Diagnostic criteria for PE.
\r\n\t
",isbn:"978-1-83962-547-3",printIsbn:"978-1-83962-546-6",pdfIsbn:"978-1-83962-548-0",doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!0,hash:"e5ba02fedd7c87f0ab66414f3b07de0c",bookSignature:" John P. Tiefenbacher",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/10765.jpg",keywords:"Managing Urbanization, Managing Development, Managing Resource Use, Drought Management, Flood Management, Water Quality Monitoring, Air Quality Monitoring, Ecological Monitoring, Modeling Extreme Natural Events, Ecological Restoration, Restoring Environmental Flows, Environmental Management Perspectives",numberOfDownloads:null,numberOfWosCitations:0,numberOfCrossrefCitations:null,numberOfDimensionsCitations:null,numberOfTotalCitations:null,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"January 12th 2021",dateEndSecondStepPublish:"February 9th 2021",dateEndThirdStepPublish:"April 10th 2021",dateEndFourthStepPublish:"June 29th 2021",dateEndFifthStepPublish:"August 28th 2021",remainingDaysToSecondStep:"23 days",secondStepPassed:!1,currentStepOfPublishingProcess:2,editedByType:null,kuFlag:!1,biosketch:"A geospatial scholar working at the interface of natural and human systems, collaborating internationally on innovative studies about hazards and environmental challenges. Dr. Tiefenbacher has published more than 200 papers on a diverse array of topics that examine perception and behaviors with regards to the application of pesticides, releases of toxic chemicals, environments of the U.S.-Mexico borderlands, wildlife hazards, and the geography of wine.",coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"73876",title:"Dr.",name:"John P.",middleName:null,surname:"Tiefenbacher",slug:"john-p.-tiefenbacher",fullName:"John P. Tiefenbacher",profilePictureURL:"https://mts.intechopen.com/storage/users/73876/images/system/73876.jfif",biography:"Dr. John P. Tiefenbacher (Ph.D., Rutgers, 1992) is a professor of Geography at Texas State University. His research has focused on various aspects of hazards and environmental management. Dr. Tiefenbacher has published on a diverse array of topics that examine perception and behaviors with regards to the application of pesticides, releases of toxic chemicals, environments of the U.S.-Mexico borderlands, wildlife hazards, and the geography of wine. More recently his work pertains to spatial adaptation to climate change, spatial responses in wine growing regions to climate change, the geographies of viticulture and wine, artificial intelligence and machine learning to predict patterns of natural processes and hazards, historical ethnic enclaves in American cities and regions, and environmental adaptations of 19th century European immigrants to North America's landscapes.",institutionString:"Texas State University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"6",institution:{name:"Texas State University",institutionURL:null,country:{name:"United States of America"}}}],coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"12",title:"Environmental Sciences",slug:"environmental-sciences"}],chapters:null,productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"194667",firstName:"Marijana",lastName:"Francetic",middleName:null,title:"Ms.",imageUrl:"https://mts.intechopen.com/storage/users/194667/images/4752_n.jpg",email:"marijana@intechopen.com",biography:"As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophanides",surname:"Theophile",slug:"theophanides-theophile",fullName:"Theophanides Theophile"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1373",title:"Ionic Liquids",subtitle:"Applications and Perspectives",isOpenForSubmission:!1,hash:"5e9ae5ae9167cde4b344e499a792c41c",slug:"ionic-liquids-applications-and-perspectives",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/1373.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"57",title:"Physics and Applications of Graphene",subtitle:"Experiments",isOpenForSubmission:!1,hash:"0e6622a71cf4f02f45bfdd5691e1189a",slug:"physics-and-applications-of-graphene-experiments",bookSignature:"Sergey Mikhailov",coverURL:"https://cdn.intechopen.com/books/images_new/57.jpg",editedByType:"Edited by",editors:[{id:"16042",title:"Dr.",name:"Sergey",surname:"Mikhailov",slug:"sergey-mikhailov",fullName:"Sergey Mikhailov"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"878",title:"Phytochemicals",subtitle:"A Global Perspective of Their Role in Nutrition and Health",isOpenForSubmission:!1,hash:"ec77671f63975ef2d16192897deb6835",slug:"phytochemicals-a-global-perspective-of-their-role-in-nutrition-and-health",bookSignature:"Venketeshwer Rao",coverURL:"https://cdn.intechopen.com/books/images_new/878.jpg",editedByType:"Edited by",editors:[{id:"82663",title:"Dr.",name:"Venketeshwer",surname:"Rao",slug:"venketeshwer-rao",fullName:"Venketeshwer Rao"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"4816",title:"Face Recognition",subtitle:null,isOpenForSubmission:!1,hash:"146063b5359146b7718ea86bad47c8eb",slug:"face_recognition",bookSignature:"Kresimir Delac and Mislav Grgic",coverURL:"https://cdn.intechopen.com/books/images_new/4816.jpg",editedByType:"Edited by",editors:[{id:"528",title:"Dr.",name:"Kresimir",surname:"Delac",slug:"kresimir-delac",fullName:"Kresimir Delac"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3621",title:"Silver Nanoparticles",subtitle:null,isOpenForSubmission:!1,hash:null,slug:"silver-nanoparticles",bookSignature:"David Pozo Perez",coverURL:"https://cdn.intechopen.com/books/images_new/3621.jpg",editedByType:"Edited by",editors:[{id:"6667",title:"Dr.",name:"David",surname:"Pozo",slug:"david-pozo",fullName:"David Pozo"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"57389",title:"Pharmacological Opportunities for Prevention of Preeclampsia",doi:"10.5772/intechopen.70164",slug:"pharmacological-opportunities-for-prevention-of-preeclampsia",body:'Preeclampsia (PE) is defined as a dysfunction in pregnancy, with a prevalence of 5–8% associated with multiple complications and high rates of mortality around the globe. Around the world about 50,000–60,000 deaths contributing to PE occur annually, which describes its impact in maternal and fetal mortality globally. Hypertension is the main characteristic of this disease, with a blood pressure ≥140/90 mmHg assessed two occasions with a 4-h time laps in between one another. The presence of proteinuria (≥0.3 g/24 h or positive dipstick proteinuria) after the 20th week of gestation or the appearance of thrombocytopenia in absence of proteinuria may also work as a diagnostic criterion [1, 2].
The risk of complications in the mother increases as a consequence of endothelial dysfunction. The risk of multiple cardiovascular diseases may increase in the fetus as well as in the mother later in life [2].
PE is a multisystem disease, a particular human syndrome that is specific to pregnancy. There are multiple factors present in the pathogenesis of preeclampsia, which go from genetic to environmental, but there is not a clear correlation between these factors and the development of PE. The scarce investigation in humans is due to legal and ethical limitations. Multiple animal models have been tested to explain the pathophysiology and characteristics of these diseases. Although there have been a great contribution, none have been able to completely reproduce all the events present in the human disease, such as the impaired trophoblast invasion and the disappearance of clinical findings once the placenta is removed. Still animal models have given us the biggest contributions to the understanding of the etiology of the disease and have allowed us to test the effectiveness of multiple pharmacological interventions.
The actual recommendations for protecting the life of the mother are the interruption of pregnancy. The appropriate time for interruption of pregnancy is subject of further investigation to facilitate decision making. Gestational age of the fetus should take into account while making decision without increasing the risk for the mother to develop severe complications that could lead to a maternal death. Despite all of these, the available medication for preventing or curing PE is not completely effective. For this reason, the objectives of this chapter are recommendations on the management of PE as well as new findings of the pathogenesis of the disease. Also, to establish rules and different genetic biomarkers to improve the identification of high risk patients and potential therapeutic targets that should be the focus of our attention in the coming years to prevent or manage adequate PE and avoid the consequences that involve one maternal death.
Preeclampsia is a disease defined as the presence of hypertension after the 20th week of gestation, accompanied by new onset proteinuria or by signs and symptoms regarding organ damage, these may include visual disturbances, headaches, epigastric pain and/or rapid development edema. All of these manifestations are a result of the inadequate trophoblastic invasion that occurs during the second half of pregnancy and results in endothelial dysfunction [1, 2].
Many of the signs and symptoms that involve this syndrome might not become clearly evident, due to the complexity of PE, despite the systemic damage caused by endothelial dysfunction. The most notorious of these manifestations is the elevation of the blood pressure. The diagnostic criteria have evolved over time in order to achieve a specific and timely diagnosis.
Diagnosis includes the development of hypertension after 20 weeks of gestation in a woman with previous normal blood pressure. Hypertension is not the only criteria for diagnosing PE, in some cases other criteria such as proteinuria of new onset could be associated, or, in the case of absence of proteinuria, the diagnostic can be established with thrombocytopenia of new onset, pulmonary edema or visual or neurological disorders among others (Table 1) [1, 2].
Blood pressure | 1. *SBP ≥ 140 or **DBP ≥ 90 mmHg on two occasions within 4 h after 20 WG in a woman with previous normal blood pressure. |
2. If SBP ≥ 160 or DBP ≥ 110 mmHg, hypertension can be confirmed in a short time interval (minutes) to facilitate the initiation of antihypertensive therapy. | |
Plus | |
Proteinuria | • ≥ 300 mg in 24 h urine (can be extrapolated to the time of collection). |
• Ratio protein/creatinine ≥ 0.3 mg/dL. | |
• Dipstick reading of (≥ 1+) used only if there are no other quantitative method. | |
Or in the absence of proteinuria and or hypertension, with new onset of any of the following: | |
Central nervous system | 1. Headache/visual disturbances. |
2. Eclampsia. Reversible posterior leukoencephalopathy syndrome. Cortical blindness or retinal detachment. Glasgow < 13. Stroke. Transient ischemic attack. Reversible ischemic neurological deficit. | |
Cardiorespiratory system | 1. Chest pain. Sat O2 < 97%. |
2. Severe uncontrolled hypertension over a period of 12 hours despite the use of 3 antihypertensive drugs. Oxygen saturation < 90%. Intubation, Pulmonary edema. The need of inotrope therapy. | |
Hematology | 1. Leukocytosis. Elevation of ***INR or Prothrombin time. Thrombocytopenia. |
2. Platelet count less than 100,000/microliter. Blood transfusion requirement. | |
Kidney | 1. Elevation of serum creatinine and/or serum uric acid. |
2. Acute kidney injury. Requirement for dialysis. | |
Hepatic | 1. Nausea. Threw up. Epigastric pain right upper quadrant pain. Elevated liver enzymes, bilirubin or lactate dehydrogenase. Hypoalbuminemia. |
2. Liver failure. Bruising or hepatic rupture | |
Feto-placental unit | 1. Abnormal Fetal Hearth Rate. Oligohydramnios. |
2. Abruption placentae with fetal and maternal morbidity. Fetal death. |
Diagnostic criteria for PE.
(SBP) systolic blood pressure
(DBP) diastolic blood pressure.
(INR) International normalized ratio
1. Warning signs; 2. Complications
PE is classified as:
Mild: presence of hypertension with sustained SBP values: 140–159 mmHg or DBP 90–109 mmHg, proteinuria or one of the warning signs presented in Table 1.
Severe: presence of SBP > 160 mmHg or DBP > 110 mmHg, proteinuria or one of the complications presented in Table 1.
There are several guides with different diagnostic criteria and all them coincide that the evidence of target organ damage can substitute the proteinuria accompanied to hypertension.
The first consideration in the management of PE must be maintaining the safety of the mother and fetus. The second consideration has to be a delivery of a mature newborn that does not require prolonged intensive care (Table 3) [1, 2].
Once PE is diagnosed, subsequent management will depend on: the results of maternal and fetal assessment, gestational age, presence of labor or premature rupture of the membranes, vaginal bleeding and the mother wishes to extend the pregnancy.
An expectant treatment, without pharmacological intervention is frequently carried on, in the medical practice, in woman with mild PE that have a blood pressure that does not exceed SBP <160 mmHg and DBP <110 mmHg, and without complications. Nevertheless, this practice has been declining because new data indicates a greater benefit with the use of drug therapy. However, antihypertensive treatment is limited to methyldopa, labetalol and nifedipine, these interventions reduce high hypertension, but do not diminish the progression of PE [2].
For women with severe PE presented before fetal viability, after interruption of pregnancy maternal stabilization is recommended. This must be done in an intensive care unit and combine the use of labetalol, hydralazine and even nitroglycerin or sodium nitroprusside in addition to the drugs mentioned in previous lines [2] (Table 3). The use of magnesium sulfate deserves a special mention as it is used primarily to prevent eclampsia and not to promote a hypotensive effect. However, when used in combination with antihypertensive therapy, it reduces morbidity in patients with critical elevation in blood pressure [3].
Monitoring is essential to prevent serious complications of PE and it should be continued even after the establishment of treatment. Complications are divided into maternal and fetal (Table 2) [2].
Maternal | Fetal |
---|---|
• Eclampsia • Reversible posterior leukoencephalopathy syndrome • Cortical blindness • Retinal detachment • Transient ischemic attack • Severe hypertension • Pulmonary edema • Myocardial infarction • Thrombocytopenia • Acute renal damage • Liver dysfunction • Abrupt placenta • Maternal death | • Prematurity • Low birth weight • Intrauterine growth restriction • Delivery of a death product |
Complications of PE.
Despite efforts to treat PE, treatment is symptomatic and focused on controlling blood pressure, so the recommendation remains in the completion of the deed at the right time. As for the time of delivery, it is preferred to prolong gestational age as long as possible, however, in severe PE; antihypertensive treatment and termination of pregnancy are recommended, if it is greater than 34 weeks. If the pregnancy is less than 34 weeks and both mother and the product are stable it is recommended to continue the pregnancy and the administration of corticosteroids (Table 3) [1].
Mild PE | Severe PE |
---|---|
Antihypertensive treatment* | |
24–<35 WG | |
Corticosteroids 48 h before termination of complicated pregnancy | Corticosteroids 48 h and immediate termination of pregnancy after maternal stabilization |
≥35 WG | |
Should be immediate termination of pregnancy | Immediate termination of pregnancy |
Treatment of PE.
Methyldopa, labetalol, nifedipine, hydralazine.
WG, weeks of gestation.
Currently, there are multiple criteria for better management of PE, but the only cure is the interruption of pregnancy, in which many times is a difficult decision for both the physician and the mother, due to the psychological burden, social, economic morbidity and mortality.
Despite advances in the treatment of PE and decades of research, the results of medical interventions have failed to significantly decrease the morbidity and mortality of this disease. The main reason seems to be the multifactorial causes of the pathogenic processes that lead to the development of PE. Its inception happens late in pregnancy that is why the approach to manage these patients must be prevention. Knowing the factors that trigger the pathophysiological mechanism that lead to PE, is essential for its prevention. However, the etiology is still unknown and research in these patients is complicated due to the ethical considerations that must be taken into account. The multifactorial origin and the difficulty of carrying out studies in the early stages of pregnancy can endanger for both mother and fetus [4].
There are currently 236,008 clinical trials registered in clinicalTrials.gov, of which only 3% are focused on pregnancy and of the latter 6.4% is about PE. Of all clinical trials dedicated to PE, 47.9% focus on strategies to improve treatment, 22.2% of the clinical trials aim to improve the diagnosis or its establishment in the early stages and 16.7% aims to establish the utility of new biomarkers, for both diagnostic and monitoring. Finally, only 10.7% of the clinical trials registered until February 1, 2017, are focused on the prevention of PE (Figure 1).
Clinical trials registered until February 1, 2017. Data from: clinicaltrails.gov.
Another aspect that should be taken under consideration is that more than half of the clinical trials directed to PE are carried out in regions classified as first world, such as Europe and North America, whereas research in the rest of the world only constitutes 40%, despite the fact that developing countries are the ones that bear the greatest burden of morbidity and mortality caused by this disease (Figure 2).
Clinical trials on PE reported by region. Reference: Clinicaltrials.gov.
The understanding of the development of the placenta in patients with high risk pregnancy is essential to comprehend the pathophysiology for developing strategies of prevention.
Traditionally, the pathophysiological process has been divided into three stages.
The invasion by the villi of the cytotrophoblasts in the decidual arteries and the myometrium arteries decreases to 56% and 76–18%, respectively. Neither endothelial cells nor smooth muscle cells are replaced by trophoblasts, therefore they are not affected. Thus, the uterine arteries, which have a smaller diameter, retain their vasoconstrictor potential which is the source of placental hypoxia, maladaptation of blood flow, as well as the phenomenon of ischemia—reperfusion of the uterus and placenta [4, 5].
Inadequate trophoblastic invasion produces an imbalance between angiogenic factors, such as the vascular endothelial growth factor (VEGF), placental growth factor (PIGF) and anti-angiogenic factors as soluble fms-like tyrosine kinase 1 (sFlt-1 or sVEGFR1), a splice variant of the VEGF-receptor. During the first 10 weeks of gestation, sFlt-1 is elevated, even more in pregnant women with PE than in those healthy, with a second peak between 26 and 29 weeks.
In preeclamptic pregnancies, sFlt-1 is produced excessively by the placenta much earlier than in healthy pregnancies and secreted into the maternal blood stream, where it is thought to bind and neutralize VEGF, and the VEGF subfamily member; PlGF with high affinity. This causes a decrease of VEGF and PlGF in maternal blood, and VEGF-signaling in the endothelial cells is disrupted as less VEGF receptors are bound. However, it is still unclear what causes the excessive sFlt-1 production and release. It could be shown that hypoxias, as well as the placental mass are triggers, but there may be others. The consequence of blocking VEFG and PIGF is a poor formation of the vascular bed of the placenta [6].
Another event that occurs early in the onset of symptoms, is the elevation of certain inflammatory cytokines such as alpha tumor necrosis factor (TNF-α) and interleukins IL-2, IL-4, IL-6, IL-8, IL-10, IL-12 and IL-8; these may initially lessen compared to healthy pregnant women. As the disease progresses over time, such cytokines showed an elevation in plasma levels. The activation of macrophages and natural killer cells leads to lysis of the trophoblast decidua cells [6].
Women that have a predisposition to develop PE, prior to the trophoblast invasion a generalized breakdown of the spiral arteries occurs, causing changes in preexisting vascular bed [4].
At the beginning of the pregnancy, a state of hypoxia is presented, however, at the 10th week an increase of oxygen by the spiral arteries to overcome this state. In PE, placental dysfunction results from an inadequate placental trophoblast invasion which results in a release of placental products into maternal circulation. Placental dysfunction causes a prolonged state of hypoxia throughout the whole pregnancy resulting in high levels of hypoxia-induced factor-1 (HIF-1α) during gestation. The prolonged state of hypoxia causes an oxidative damage to the placental barrier which increases fetal hemoglobin gene expression and free fetal hemoglobin accumulation in placenta. The accumulation of fetal hemoglobin and its metabolites due to is toxicity results in damage through three pathways [4, 7].
1st pathway: ferrous hemoglobin (Fe2+) binds to nitric oxide (NO), a potent vasodilator, and reduces the availability inducing vasoconstriction.
2nd pathway: Fe2+ hemoglobin is oxidized and reactive oxygen species (ROS) are released, provoking endothelial damage.
3rd pathway: the heme group of the hemoglobin molecule triggers an inflammatory response by activating neutrophils and cytokines production [4, 7].
The phenomenon of reoxygenation hypoxia generates oxidative stress, which induces placental dysfunction. Many cellular stress situations, such as an alteration in the redox state alters the maturation of proteins, leading to the accumulation of misfolded proteins in the lumen of the endoplasmic reticulum (ER), thereby producing a condition called “endoplasmic reticulum stress”, which triggers an adaptive response, called “unfolded protein response”, which aims to reduce the decrease proteins. In PE, the phenotype of placenta and intrauterine growth restriction are correlated with ER stress. In urine, misfolded proteins can be found, making it a viable biomarker for the Congo red test [7, 8].
The mother mounts an immune response against fetal trophoblast, which is detected as an alloantigen. PE could be consequential to a secondary inflammatory response derived from microparticles of microvilli of the syncytiotrophoblast (STMBs). The uterus-fetal perfusion begins close to the end of the first trimester, and during the second and third trimester high levels of STMBs are detected in maternal circulation. The release of STMBs is affected by oxidative stress, which increases its release to maternal circulation creating an inflammatory response [4, 6].
Reactive oxygen species (ROS), like nitric oxide (NO), superoxide (O−2), hydrogen peroxide (H2O2), hydroxyl radical (OH) and peroxynitrite (ONOO−) are present all the time. Oxidative stress from unbalanced free radical formation is produced within the trophoblast cell, the sources may vary from O, eNOS uncoupling, NADPH oxidase and mitochondria. Proxynitrite formation, lipid peroxidation, protein modification, matrix metalloproteinase (MMP) activation and DNA damage contribute to endothelial dysfunction and are a result of the combination of these events [7, 9].
The main catalysts of O−2 are the antioxidant enzyme, superoxide dismutase (SOD) that converts it to H2O2 and water. H2O2 is immediately neutralized by the enzyme, catalase (CAT). PE is one of several conditions that after the ischemia-reperfusion, produces O−2 and by converting xanthine dehydrogenase (XD) to xanthine oxidase (XO) causes oxidative damage. Additionally, ATP metabolism in ischemic tissues forms hypoxanthine (HX) as a breakdown product. Xanthine and HX are converted into uric acid by XO, which also does the conversion of oxygen to O−2 and H2O2. In PE, superoxide generation by XO has been shown in placental reperfusion injury. Since PE is characterized by hyperuricemia, XO is presumably the source of uncontrolled ROS production when the concentration of its oxidase form is increased [7, 9].
Another source of O−2 formation is NADPH oxidases. NADPH oxidase is a membrane-bound enzyme complex that catalyzes a one-electron reduction of oxygen and its transference to form O−2. It has been demonstrated that NADPH oxidase isoform, NOX1, is overexpressed in syncytiotrophoblast of preeclamptic placentas [7, 9].
3-nitrotyrosine residues have been observed in normal and complicated pregnancies, predominantly, in endothelium, surrounding smooth muscle and villous stroma. One of the key targets of ONOO− in PE is p38 mitogen-activated protein kinase (p38 MAPK), that has appeared significantly nitrated in placentas from preeclamptic women compared to normotensive controls. Activation of the p38 MAPK pathway plays an important role in the release of pro-inflammatory cytokines and the induction of enzymes such as COX-2 which controls connective tissue remodeling in pathological conditions. Inducible nitric oxide synthase (iNOS) expression, induction of VCAM-1 and, other adherent proteins along with other inflammatory-related molecules, and the effect of nitration of p38 MAPK in PE is currently under investigation for their use as molecular targets [7, 9].
But, not all free radicals cause disturbances in the organism and NO is an example. NO is a potent vasodilator, which acts on GTP to produce cGMP that causes relaxation of smooth muscle. It mediates endothelial function by regulating vascular tone, platelet aggregation, leukocyte adhesion and smooth muscle cells development. It is synthetized by the NOS family of enzymes, which consist in three isoforms: nNOS or neuronal isoform, iNOS the inducible and eNOS the endothelial NOS, formed from the reduction of
A reduction of vasodilating agents, such as NO and platelet PG2, a proliferation of vasopressor agents and platelet aggregating agents, such as thromboxane A2 (TX A2) and endothelin-1, alter the endothelial function. As a consequence of this imbalance, higher sensitivity combined with angiotensin II results in a state of vasoconstriction with an increased peripheral vascular resistance that creates an increase in blood pressure. Endothelial permeability is increased as well [10].
Regulation of the fetoplacental vascular reactivity, trophoblast invasion and apoptosis, and adhesion and aggregation of platelets in the intervillous space are all affected by NO, the main vasodilator in placenta.
At the early stages of pregnancy, a hemodynamic adaptation as a response of an extra need for perfusion is induced by an increase in NO and a reduction in ADMA. As well, this adaptation permits uterine relaxation, which is necessary for intrauterine growth. Towards the end of pregnancy, the muscle fibers of the uterus suffer change, due to an increase in physiological ADMA, to undergo greater contractile activity and antagonize the effect of NO. In pregnancy with high risk of PE, ADMA levels increase to higher than normal, reason why many studies have suggested the possibility of using it as a biomarker of endothelial dysfunction [11, 12].
TXA2 works as a vasoconstrictor and in patients with high risk of PE, its levels increase all together with the circulating levels of TXB2, one of its metabolites. TXA2 is produced in platelets and endothelial cells and is one the many molecules derived from arachidonic acid through prostaglandin H synthase (PGHS). The TXA2 receptor (TP) mediates the constrictor effects of TXA2 in vascular smooth muscle.
The vasoconstrictive effects of TxA2 in PE are amplified because of their ability to potentiate the vasoconstrictor effects of angiotensin II and endothelin-1. NO and I2 (PGI2) inhibit prostaglandin TxA2 actions through TP receptor desensitization; however, in pregnancies with PE, NO production and PGI2 are affected. Research profiles of DNA methylation of omental arteries reveal that the gene, thromboxane synthase (TBXAS1), is hypomethylated, even more significantly in the vessels of women with PE and this was associated with the increased expression of thromboxane synthase in the omental arteries women with PE. Taken together, these data suggest that, in PE, there is an imbalance in the production of vasoconstrictors (TxA2) and vasodilator prostanoids (PGI2), modulated by epigenetic modifications [13].
It is also reported in the literature the presence of autoantibodies against angiotensin receptor 1 (AT-1). These autoantibodies have a pharmacological effect similar to that of angiotensin II agonist. Stimulation of the AT-1 receptor by these circulating autoantibodies could also be responsible for hypertensive symptoms in PE, as the concentration of circulating autoantibodies increases after 20 weeks of gestation [6, 14].
PEs pathogenic process begins during the first quarter, long before clinical signs are evident. Therefore, it is difficult to identify early biomarkers. Although there is no perfect way to predict the development of PE, it is possible to distinguish between women who have a high risk of developing PE of those whom have a low risk (Table 4).
High risk factors | Moderate risk factors |
---|---|
PE in previous pregnancies. Women who have PE in the first pregnancy have 7 times more risk of developing PE in a second pregnancy (RR 7.19; 5.85–8.83). Hypertension in pregnancy. The prevalence of chronic hypertension in women who develop PE is 12% (RR 5.2; 1.5–17.2). Renal disease. The prevalence of renal disease in women who develop PE is 5.3%. Diabetes mellitus 1 and 2. The probability of PE almost quadruples if diabetes is present before pregnancy (RR 3.56; 2.54–4.99). Autoimmune diseases. Women who develop PE are more likely to have an autoimmune disease (RR 6.9; 1.1–42.3). Antiphospholipid syndrome significantly increases the risk of developing PE (RR 9.72; 4.34–21.75). | Primigravid. Nulliparity almost triples the risk of PE (RR 2.91; 1.28–6.61). Maternal age. The risk increases 30% for every completed year after 34.9. The risk increases twice in nulliparous ≥40 years (RR 1.68; 1.23–2.29). Interval intergenesic >10 years. The risk of PE is about the same as that of nulliparous (RR 1.12; 1.11–1.13). Body mass index (BMI) ≥ 35 kg/m2. The risk of PE is increased up to 50% (RR 4.39; 3.52–5.49). Family history of PE. This almost triples the risk of PE (RR 2.90; 1.70–4.93). Multiple pregnancy. Twin pregnancy nearly triples the risk of PE (RR 2.93; 2.04–4.21), while a triplet pregnancy nearly triples the risk of twin pregnancy (RR 2.83; 1.25–6.40). |
However, these factors predict only 30% of women who develop PE. Biomarkers in maternal blood have a modest predictive potential. Prediction of early onset of PE at the end of the first quarter of pregnancy can be done using Doppler ultrasound combined with plasma levels of placental growth factor and protein-A associated with pregnancy (PAPP-A) [15].
An effective biomarker to predict of the onset of PE has not been established, some the most promising biomarkers are listed in Table 2. The heterogeneity of the pathogenesis of PE makes it difficult to establish a single biomarker as a predictor of the disease; the best approach might be a combination of markers. However, much research and development of criteria are needed. There is a need for biomarkers that could also apply to patients that apparently do not have any risk factors for developing PE, and research should expand its investigation regarding these patients (Table 5).
Biomarker | Characteristics | Studies |
---|---|---|
sFlt-1/PlGF | It has been included sFlt-1/PlGF ratio into German PE guidelines for care. A ratio of sFlt-1/PlGF: 38 at any time during pregnancy is considered as suspected PE, while PE is considered diagnostic of figures 85 and 110 before and after 34 weeks of gestation, respectively. | Stepan in 2015 shows that circulating levels of sFlt-1 are increased significantly more a month before the appearance of the first clinical symptoms detectable. In the case of PlGF, significantly lower concentrations are observed in women who subsequently present placental dysfunction since the end of the first quarter. They concluded that further studies are needed to demonstrate the benefits of using the ratio of sFlt-1/PlGF in terms of reduction of maternal and fetal risks and resource optimization [17]. |
Soluble endoglin (Seng) | A truncated form of the receptor for β1-transforming growth factor (TGF-β1) and TGF-β2 that interferes with the binding of TGF-β1 to its receptor, and thereby affects the production of nitric oxide, vasodilation and capillary formation by the endothelial cells in vitro. | Levine et al. showed in 2006, in a nested case study that circulating levels of soluble endoglin increased from 2 to 3 months before the clinical onset of PE controls. After the onset of the disease, the average level of serum in women with PE remains high until the end of pregnancy (31.0 ng/ml, as compared to 13.3 ng/ml in controls (p < 0.001) A higher level of soluble endoglin is usually accompanied by an increase in the proportion of sFlt1: PlGF [18]. |
PAPP-α | A highly glycosylated protein that is produced by trophoblast cells in development has proven to be an insulin-like growth factor. Therefore, as expected, low serum levels of PAPP-α are associated with a higher incidence of PE. | The studies are contradictory, while some show association with low levels of PAPP-α, others observed elevations in serum. Both observations were made by Bersinger et al. In two separate case-control study in 2003 and 2004, respectively [19, 20]. |
Activin-A | This is a glycoprotein member of the TGF-β family that is released by the placental-fetus unit during pregnancy. Activin-A is involved in various biological activities [21]. | A case-control study conducted in 2004 by Ong et al. found that levels of activin-A are higher PE than in normal pregnancies. It has been observed that an increase in activin-A occurs before 14 weeks of gestation in pregnancies with PE. |
PP-13 | A 32-kd dimer protein is one of 56 known placental proteins, produced exclusively by placenta and it facilitates trophoblast invasion and maternal artery remodeling [22]. A higher magnitude of increase of PP13 from the first to the third trimester was observed in PE [23]. | Gonen et al., in 2008 conducted a study of cases and controls in pregnancy between 5 and 7 weeks and determined the relation of lower values of PP-13 in PE than in normal pregnancies. The increase of PP-13 in maternal blood seems to coincide with STBM release as the PE advances. |
Cystatin C | A protease inhibitor is widely used by clinicians as a sensitive marker for renal function and for estimating glomerular filtration rate. Increased levels of cystatin-C may be attributed to an increased placental production. | Thilaganathan et al. in 2009 conducted a nested case study to determine levels of cystatin C, a marker set for kidney function, which increases progressively as the glomerular filtration rate falls. In PE, placental expression of cystatin C is significantly increased in the first trimester of pregnancy compared to those with normal pregnancy [24]. |
Fetal hemoglobin | Oxidative damage induces placental production and leakage in the fetal-maternal hemoglobin barrier. | Recent studies have identified it as a predictor in the first and second quarters [25]. |
ADMA and homocysteine | Serial measurements of their concentrations may be useful to identify women at risk [26]. | López-Alarcón et al., in a cohort study in 2015 found that ADMA and homocysteine (Hcy) increases gradually throughout pregnancy with PE, but remains constant in women without complications. ADMA and homocysteine increase 1 month prior to the onset of PE. Increases of up to 80 nmol of ADMA and Hcy 1000 nmol to 1, a month prior to the onset of PE. This has demonstrated the best potential for prediction |
miRNA | miR-16 is stimulated by hypoxia and inhibits migration of cytotrophoblast cells [27], it represses production of VEGF receptors in mesenchymal stem cells derived from the decidua (MSCs), and induces cell cycle arrest in the transition G0/G1 [28]. miRNA-155 overexpression reduces the expression of NOS [29]. C19MC miRNAs are downregulated exclusively associated with preeclampsia [30]. | There are more angiomiRNAs that have been found and vary on their level of expression. However, there is still a lack of investigations to understand their role as biomarkers. |
Potential biomarkers in preeclampsia.
sFlt-1, soluble fms-like tyrosine kinase 1; PlGF, placental growth factor; ADMA, asymmetric dimethylarginine; PAPP α, pregnancy-associated plasma protein-A; PP-13, placental protein 13; miRNA, microRNA; STMB, syncytiotrophoblast microvesicles.
According to an study conducted by Hofmeyr et al., supplementation of calcium in women that have a low calcium intake and mild risk of PE have a relative risk of 0.48 (95% CL 0.33–0.69). However, patients that have a low calcium intake and a high risk of PE displayed a major benefit (RR .22; 95% CL 0.12–0.42). Low levels of calcium increase vasoconstriction resulting in high blood pressure, by liberating parathyroid hormone or releasing renin, and consequently increasing intracellular calcium in vascular smooth muscle. Parathyroid hormone release and intracellular calcium levels are reduced with calcium administration [31].
The inhibition of thromboxane A2 formation without affecting the production of prostacyclins, gives acetylsalicylic acid in low doses an anti-platelet aggregating an anti-vasoconstrictor effect. This justifies its use in PE; however, the results have been controversial about the positive role of its administration at the onset of the pregnancy and the severity of its use.
Campos concluded, from a systemic review, that since there are no pharmacological alternatives, physicians should administer low doses of aspirin from 60 to 150 mg per day starting in the first quarter through to week 16. Administration should be performed overnight because it helps in reducing the risk of PE [32].
Since endothelial dysfunction and impaired bioavailability of NO are taxpayers of maternal manifestations of PE, supplementation with exogenous NO donors would be an apparent solution.
Trapani et al. conducted a study in which nitroglycerin transdermal patches were applied into the mother’s abdomen to improve the uteroplacental circulation. They reported an increase of the blood flow in the uterine and umbilical arteries. However, further investigation is needed for their effect reducing the incidence of PE [33].
Groten et al. found that pentaerythritol tetranitrate, an organic nitrate of prolonged action, improves uteroplacental perfusion in women at risk of PE, as well as reducing its frequency, growth restriction and premature births it may cause in these women [34].
Moreover
Camarena et al. published in 2016 a clinical trial which included 100 pregnant women at high risk for PE to estimate the effectiveness and safety of
As seen in Figure 3, we can establish several moments as opportunities for prevention or management of PE, the best opportunity for treating PE is prior to pregnancy by identifying women with high risk and creating strategies to prevent the development of the disease. During pregnancy, several potential targets could modify its course; we listed in a timeline the molecules that have an implication in the pathogenesis of PE.
The pathological processes and the clinical manifestations are listed chronologically, with the key moments for pharmacological intervention pointed out at every stage of the pregnancy.
PE is a serious complication of pregnancy, which has a high rate of morbidity and mortality worldwide. Due to the complexity of PE, and despite the systemic damage caused by endothelial dysfunction, many of the signs and symptoms that make up this syndrome may not be clearly evident, being the most notorious sign an elevation of the blood pressure. The diagnostic criteria have evolved over time in order to achieve a timely and specific diagnosis, but this has only caused a more complex evaluation, so it requires new tools to achieve an early and accurate diagnosis of the PE.
Antihypertensives are an alternative for the treatment of PE, however, they stretch the pregnancy until the product is viable to live outside the uterine environment, shortening gestation. The outcome using hypertensives is not always favorable for the mother and the fetus and their effect on PE is variable.
During the early stages of placentation, various changes may occur due to intrinsic factors, so this should be the focus of investigation. However, invasive procedures to pregnant women are not acceptable because of the risk they might represent without any notable benefit.
The combination of several biomarkers could contribute to identify women with mild and high risk of developing the disease, which is the best strategy for prevention and management of PE.
In past years, a lack of therapeutic options regarding PE was notorious. However, new opportunities have surged in present years such as, inmunomodulators, antioxidants, angiomRNAs and nitric oxide donors, which are still under investigation but have shown promising results. Nevertheless, prevention persists as the principal strategy to reduce morbi-mortality of PE. The obstetrician is responsible for evaluating the individual options each patients has, even before conception and research should focus on developing new and better strategies.
It refers to the discomfort that occurs in the groin area of abdominal wall.
The most common causes of groin pain include:
Pulling on a muscle, tendon, or ligament in the leg
Hernia
Hip joint disease or injury
Less common causes include:
Inflammation of the testicle or epididymis and related structures
Torsion of the spermatic cord attached to the testicle (testicular torsion)
Tumor of the testicle
Kidney stones
Inflammation of the large and small intestine
Skin infection
Swelling of the lymph nodes
Urinary infection
This groin pain is perceived, integrated, transmitted and evaluated by neurons and the nervous system, but we have not yet elucidated how this process takes place. Such is the profuse network of nerves that cover the area, that their involvement is a not uncommon phenomenon (Figure 1).
Nervous system in the groin hernia area (3D 4Medical app).
In fact, the most frequent surgical reason is inguinal pain resistant to conservative treatments. Besides, poor preoperative pain control is a key factor in developing acute and chronic postsurgical pain (CPSP; Figure 2).
Predictability of the appearance of CPSP.
Each patient who develops CPSP has a specific genotype, medical history, previous experiences, beliefs and psychosocial conditions related to their pain; but, in general, there are some common risk factors in the development of chronic pain.
Psychosocial factors: Anxiety, depression and catastrophizing that surround the patient during the perioperative period.
Demographic factors: In some surgeries, age is a determining factor (i.e. young women for mastectomies [1]). In others, the male gender is more prone than the female [2, 3].
Genetic factors: Several authors point to the relationship of different clinical pathologies such as fibromyalgia, migraine, irritable bowel, irritable bladder, Raynaud’s syndrome … as markers of chronic postsurgical pain [4, 5].
Preoperative pain: The presence of preoperative pain has been correlated in different studies with the development of CPSP. Of all the types of surgical interventions, the hernia procedure stands out for its high preoperative pain rates [6, 7, 8, 9].
Surgical factors: Some important surgical factors may be related to the development of CPSP such as:
Duration of the operation (more than 3 h),
Surgical technique (laparoscopy vs. open),
Incision (site and type),
Experience of the surgeon,
Center where the intervention is carried out [10].
Acute postsurgical pain (APSP): Various studies show the importance of optimal APSP control to avoid chronification of postsurgical pain. Among them, surgeries such as groin, breast, hip, knee … are the most identified [11, 12, 13].
However, and despite the fact that there are different studies addressing this issue, the controversy remains dominant. To date, it can only be suggested that they do not play in favor of a better recovery or a lower probability of chronification, in addition to reducing quality of life in the process; but in no case can we establish a universally accepted causal relationship [3, 13, 14, 15, 16].
For the response to a noxious stimulus (be it chemical, thermal, pressure or any other characteristic that can cause pain), there are structures sensitive to those stimuli in the periphery: they are nociceptors [17].
Different classes of afferent nerve fibers are responsible for the communication of nociceptive information and pain:
Type Aβ: with a myelin sheath, are sensitive fibers responsible for touch and pressure.
Type Aδ: with a myelin sheath are responsible for the transmission of localized acute pain, temperature and part of the touch.
C fibers, without myelin sheath are responsible for the transmission of deep diffuse pain, smell, information from some mechanoreceptors, responses of the reflex and postganglionic arcs of the autonomic nervous system.
In a basal state, a noxious stimulus depolarizes a sensory or nociceptor neuron. The stimulation of nociceptors causes the propagation of the nerve stimulus to the dorsal horn of the spinal cord. Control at the spinal level is carried out in the gelatinous substance of Rolando (Rexed plate II) by stimulating inhibitory interneurons (Golgi II type) that cancel or reduce the nociceptive signal towards the lateral spinothalamic tract. In addition, glutamate is released, an excitatory amino acid that binds to a specific receptor, called AMPA and located in a postsynaptic neuron that transmits information to the higher centers of the CNS. Different brain centers are stimulated from the thalamus:
Periaqueductal gray substance (PAGS): Located in the midbrain, it is one of the most important nuclei and its functions are mediated by the opioid system. Its activation allows the inhibition of the painful process. It is connected with brain structures, with the ascending bundles and sends its projections to structures of the pons such as the nuclei of the raphe magnum.
Nuclei of the raphe magno: Located in the protuberance, receives connections from the ascending systems and the PAGS. It sends its axons to the first afferent synapse of the posterior horn and its nature is serotonergic.
Cerulean nucleus: Located on both sides of the fourth ventricle in the bridge. It is noradrenergic in nature.
The prefrontal cortex integrates all the information and the patient feels pain [18]. From these same superior nuclei, descending pathways are set in motion and reach the dorsal horn of the medulla again releasing endogenous inhibitory substances (mainly opioids and GABA). These inhibitory substances act by modulating the transmission of the stimulus: on the one hand, by decreasing the release of glutamate, and on the other, by hyperpolarizing the membrane of the postsynaptic neuron [19]. Inhibitory interneurons also come into play, which by releasing endogenous opioids, mimic and potentiate the inhibitory effect of the descending pathways.
Refers to pain that is associated with actual or threatened damage to non-neural tissue and involves the activation of peripheral nociceptors (IASP Taxonomy, 2015). There are three major forms of nociceptive pain:
Includes all pain originating from non-visceral structures, (i.e. skull, meninges, and teeth) and is the most common cause of consultation for almost all specialties, especially those dedicated to the locomotor system.
Extremely frequent, although in many cases it is not diagnosed as such. It is a neuromuscular dysfunction with a tendency to chronicity. It consists of a regional pain disorder, which affects the muscles and fasciae, so that the muscles involved have trigger points as essential components. In addition, regional and segmental autonomous alterations may coexist.
Dull, diffuse and poorly localized pain, referred to an area of the body surface, being frequently accompanied by an intense motor and autonomic (sympathetic) reflex response. The stimuli that can produce visceral pain are: spasm of the smooth muscle (hollow viscera), distension and ischemia.
Sometimes there is no relationship between the painful stimulus and the response that it originates in the CNS: it is then when a very important amplification of the nociceptive signal occurs, and this phenomenon is known as neuronal sensitization or neuropathy, so that the information transmitted to the brain causes a disproportionate pain reaction. This derangement occurs both at the peripheral and central levels.
Persistent pain becomes a pathological state that includes a series of elements that facilitate its generation and persistence over time. For this reason, any process that injures nerve tissues or causes neuronal dysfunction can produce neuropathic pain (NP). NP is qualitatively characterized by the absence of a causal relationship between injury and pain. Its etiology is very diverse and the relationship between etiology, pathophysiological mechanisms and symptoms is complex. NP differs from nociceptive pain in several aspects (Table 1).
Nociceptive (somatic / visceral) | Neuropathic | |
---|---|---|
Official definition | Pain caused by activation of peripheral / visceral nociceptors | Pain caused by PNS / CNS dysfunction |
Mechanism | Natural physiological transduction (nociceptor) | Ectopic pulse generation |
Symptom location | Local pain + referred | Territory of innervation of the affected nerve pathway |
No neurological topography | ||
Quality of symptoms | Common painful sensations of daily life - easy verbal description (i.e. Head ache, belly ache…) | New, unfamiliar, aberrant sensations: difficult verbal description (i.e. burning, electrical…) |
Normal neurological examination: response and aggression correspond | Hypo / hypersensitivity: response and aggression do not correspond | |
Treatment | Effective: conventional analgesia | Partially effective: antiepileptics, antidepressants |
Differences between nociceptive and neuropathic pain.
Adapted from Serra Catafau, Treatise on neuropathic pain (Adapted from SGADOR Handbook).
The balance between arousal and inhibition of the somatosensory system is dynamic and is influenced by context, behaviors, emotions, expectations, and pathology. In NP this equilibrium is broken and a loss in inhibitory currents has been demonstrated, with dysfunction in the mechanisms of production and release of GABA, a decrease in μ-opioid receptors in the dorsal root ganglia, and less receptivity to opioids in the spinal neurons. In summary, the neuronal pathological process changes in the course of injury and its pathophysiological mechanisms are evolutionary. The mechanisms that trigger NP produce:
Local inflammation
Glia cell activation
Changes in neuronal plasticity of nociceptive pain-transmitting pathways
Acute pain is an experience, usually of sudden onset, of short duration in time and with remission parallel to the cause that produces it. There is a close temporal and causal relationship with tissue injury or nociceptive stimulation caused by disease. Its duration ranges from a few minutes to several weeks. Acute pain has been attributed a “protective” function, its presence acts by preventing the individual from developing behaviors that may increase the injury or leads him to adopt those that minimize or reduce its impact. The fundamental emotional response is anxiety, with less involvement of other psychological components. Its characteristics offer important help in establishing the etiological diagnosis and selecting the most appropriate treatment. Its presence follows a classic treatment scheme such as Pain-Symptom. The most common causes of acute pain are:
Visceral pain
Gastrointestinal
Biliary
Urological
Cardiovascular
Pulmonary
Nervous system
Pancreatic
Gynecological
Muscle Skeletal Pain
Arthropathies
Chest wall pain
Fractures
Costochondritis
Tendinitis
Oral pain
Burn pain
Postoperative pain
Chronic pain extends beyond the tissue injury or organic involvement with which, initially, there was a relationship. It can also be related to the persistence and repetition of episodes of acute pain, with the progression of the disease, with the appearance of complications thereof and with degenerative changes in bone and musculoskeletal structures. Examples of this are cancer, secondary pathological fractures, osteoarthritis, postherpetic neuralgia, etc.
Chronic pain does not prevent or avoid damage to the body. Both their nature and their intensity show great variability over time, in many cases the complaints are perceived as disproportionate to the underlying disease. The most frequent repercussions in the psychological sphere involve anxiety, anger, fear, frustration or depression, which, in turn, contribute to further increasing pain perception. The socio-family, labor and economic repercussions are multiple and generate important changes in the lives of the people who suffer from it and their families: disability and dependency. The need to use drugs to relieve pain becomes a potential risk factor for use, abuse and self-prescription, not only of analgesics, but also tranquilizers, antidepressants and other drugs.
In its management, in addition to the physical aspects of pain, the other components, emotional, affective, behavioral and social, must be taken into account. The treatment scheme is complicated, we are facing the Pain-Syndrome (Table 2).
Acute Pain | Chronic pain | |
---|---|---|
Purpose | Initial-biological | Initial-destructive |
Duration | Temporary | Persistent |
Generator mechanism | Unifactorial | Multifactorial |
Affected component | Organic+++Psychic+ | Organic+Psychic+++ |
Organic response | Adrenergic: raise in heart rate, arterial hypertension, sweating, pupillary dilation | Vegetative: anorexy, constipation, less lybid, insomnia |
Affective component | Anxiety | Depression |
Physical exhaustion | No | Yes |
Therapeutic goal | Cure | Relief and adaptation |
Differences between acute and chronic pain.
All surgical intervention is associated with acute postsurgical pain (APSP) whose intensity decreases during the first days and weeks, in parallel with the tissue repair process. However, sometimes this pain lasts longer than is reasonable in relation to the surgical procedure. This fact can lead to the appearance of severe and disabling chronic pain syndromes, frequently associated with certain surgical procedures.
The definition of chronic postoperative pain (CPSP) does not find a consensus among the different authors in the literature reviewed. The most commonly used definition continues to be that of McRae [20, 21] based on the following aspects:
pain with a minimum duration of two months after a surgical procedure
after excluding other etiologies of pain
ruled out any pre-existing cause of pain (Figure 3).
Temporal evolution of postsurgical pain (adapted from Woolf and salter, science 2000; 288: 1765 [22]).
CPSP originates from the injury to the nerves and tissues inherent in the surgical process. During the immediate postsurgical period appears the breakthrough pain limited to the surgical site and its vicinity and develops through the direct activation of nociceptors, the inflammatory process and, in some cases, of direct nerve injury [23]. For this reason, the patient will present pain in the area of the surgical scar (primary hyperalgesia) and around it (secondary hyperalgesia). These changes are usually reversible and the normal sensitivity of the nociceptive system will then be restored. This type of pain, APSP, has a known beginning and an end in direct relation to tissue repair. In addition, it responds effectively to non-steroidal anti-inflammatory drugs, paracetamol, and minor or major opioids.
In the event of nerve injury during surgery, the neuropathic component of pain can immediately develop and persist in the absence of any noxious peripheral stimuli or ongoing peripheral inflammation [24]. The prerequisite for the development of CPSP is an injury to the major nerves that run through the surgical site. However, in a small group of patients, an ongoing inflammatory response may help maintain inflammatory pain and lead to a CPSP, such as that occurs after inguinal mesh hernia repair [25]. During progression from APSP to CPSP after inguinal hernia surgery:
7% of patients present severe acute pain the first 24 h;
14% of patients present subacute pain that could last until 8 weeks after surgery;
12% of patients present CPSP that could last until 12 months after surgery (80% of whom present Neuropathic component)
The incidence of chronic pain after inguinal hernia surgery rates from 5–63%, with an estimated incidence of severe chronic pain (VAS > 4) between 2% and 4%.
Inguinal hernia surgery can trigger a post-herniorrhaphy chronic inguinal pain syndrome, which can occur in up to 10% of the interventions performed [21].
The symptoms of postherniorrhaphy neuropathic inguinodynia consist of pain, paresthesias, allodynia (sensation of pain in the presence of non-harmful stimuli such as touch or pressure), pain radiating to the scrotal area, labia majora of the vagina and Scarpa’s triangle. This symptomatology also worsens with walking or hyperextension of the hip and decreases with decubitus and flexion of the thigh. These last aspects of the symptomatology make us see that the affectation of the nervous tract is the main actor of the chronic pain postherniorrhaphy [26].
There are three types of causes for the appearance of this painful syndrome:
Non-neuropathic
Reaction of the periosteum of the pubis
Keloid scar formation
Direct pressure exerted by bent or wrinkled prosthetic material (mesh) [27].
Neuropathic
Fibrosis of the perineurium of the nerves that run along the inguinal path (ilioinguinal nerve and genital branch of the genitofemoral nerve)
Compression of these by suture material, staples or prosthetic material
Direct injury to the nervous tract in a complete or incomplete manner. It can be produced by traction, direct cutting with a scalpel, or excessive thermocoagulation.
Peripheral sensitization involves lowering the discharge threshold from the peripheral terminal of the nociceptor. The molecules released in response to tissue damage and the activation of cells in the environment such as keratinocytes, mast cells, lymphocytes, platelets or the nociceptor itself, are called inflammatory soup (Substance P, calcitonin gene receptor protein [CGRP], quinines, amines, prostaglandins, growth factors, chemokines, cytokines, ATP, protons, etc.). These molecules induce morphological and functional changes in the neuron, which consequently generate an increase in the expression of structures such as the Na2+ channels and transient receptor potential cation channel subfamily V member 1 [TRPV1]; or molecules such as neuropeptides, or brain-derived neurotrophic factor [BDNF]. The interaction of these molecules with the different membrane receptors initiates an activation cascade of intracellular second messengers that modify the firing capacity of the cell, the final consequence being a greater capacity to respond to stimuli. This circumstance translates clinically into the following processes: hyperalgesia, allodynia, and spontaneous pain.
Spontaneous pain can be caused by:
An abnormal response to stimuli that normally do not cause harm (arterial heartbeat, increased temperature)
Ectopic discharges from the damaged nociceptor itself
Those produced by surrounding healthy fibers in response to the release of TNFα by damaged Schwann cells
At present, it is proposed a new state of the nociceptor, called “priming”, in which, a sensitized nociceptor, after a few hours will have a normal response to physiological stimuli, but will have an increased response to stimuli derived from inflammation. This state lasts for weeks and the hyperalgesic response to inflammatory agents is greater, which could be a possible explanation for the maintenance of chronic pain.
In a situation in which nociceptive information continues to be sent from the periphery to the dorsal horn of the spinal cord, the nociceptive neuron itself sends, from its soma (without the need for external stimulation) substance P and peptide related to the calcitonin gene (PRCG). These substances bind to neutrophils, mast cells and basophils, and release pro-inflammatory molecules: cytosines, bradykinins, histamines, cyclooxygenases, prostaglandins, eicosanoids and nerve growth factor (NGF). All this “inflammatory soup” produces changes in pH, release of ATP from injured cells, synthesis and release of nitric oxide (NO), etc., which induces amplification of the signal towards the spinal cord and higher centers and causes what is known as peripheral sensitization, which contributes in a very important manner to the maintenance of chronic pain.
If the nociceptive impulses are of great intensity or are sustained over time, plastic changes occur in the neurons of the posterior horn that facilitate the transmission of the nociceptive impulse. These changes in functionality are called central sensitization and cause specific clinical manifestations. It may represent the anatomical and physiological substrate to the fact of persistence of pain in the absence of peripheral nociceptive impulses in chronic pain, since the state of hyper-reactivity of the system would allow to explain the autonomous activity of the system in the absence of peripheral stimulus. In general terms, the following changes can be considered, which can all occur simultaneously or simply manifest some of them:
Disinhibition of the N-methyl-D-aspartate (NMDA) receptor by release of the Mg2+ ion at the first medullary synapse
Access of peripheral Aβ fibers to the nociceptive system. It is one of the causes of the phenomenon of allodynia
Dysregulation of the GABAergic system of inhibitory interneurons, which finally produces an alteration in the current of the Cl− channel.
Activation of the glia with the release of pro-analgesic substances
Alteration of the regulatory capacity of the downstream system
There is also the release of glutamate, which binds to specific receptors, which are not expressed in situations of acute pain. When activated, they contribute not only to depolarize the postsynaptic neuron, but also to generate a series of intracellular changes, which will increase the nociceptive signal. In response to peripheral sensitization, the primary afferent pathways also release substance P, resulting in an increase in signal. In situations of chronic pain there is also a reorganization of the neuronal structure: axonal collateral branches appear that increase the amount of nociceptive afferent signal.
On the other hand, a loss of efficacy of the inhibition produced by the descending pathways has been described, with a decrease in the release of endogenous opioids, and even cellular degeneration of those descending neurons, which indirectly also increases the nociceptive signal that is send to higher centers.
All these changes greatly amplify and sustain the nociceptive signal produced in the dorsal horn of the spinal cord, producing what is known as central sensitization.
The main clinical manifestations of nervous sensitization are hyperalgesia and allodynia phenomena, with the consequent increase in the extension of the painful area.
The presence of sensitization leads to the appearance of vicious circles in which there is a continuous sending of the afferent signal from the periphery to the brain centers in the absence of stimuli that generate them. This sustained stimulation leads to adaptive changes in the brain, such that the brain remains active even in the absence of noxious peripheral stimulus.
This continuous brain overexcitation conditions the effectiveness of the integrative pain response of the higher centers and the inhibitory descending pathway, in such a way that there is no inhibition proportional to the ascending amplified stimulus and the pain becomes chronic. This “centralizing” effect of the neuronal sensitization of nociceptors is one of the most relevant chronifying factors in the postoperative period of surgeries that present moderate to severe acute pain, that is not adequately controlled.
The type of pain, its location, duration and intensity determine the pharmacological approach (Figure 4).
Drugs that target peripheral sensitization: such as topical capsaicin (i.e. 8% capsaicin patch); topical lidocaine (i.e. 5% lidocaine patch); NSAIDs; paracetamol and local anesthetics.
Drugs that target central sensitization: such as serotonin reuptake inhibitors (SSRIs); tapentadol; tramadol; opioids; calcium channel ligands; adjuvants; tricyclic antidepressants; anticonvulsants and COX-2.
Pharmacological approach to chronic pain.
Blocking the pain signal before it reaches the central nervous system prior to surgery will prevent the development of central sensitization. The times that include the first consultation, the referral to the specialist, the decision of surgical treatment, the pre-anesthetic consultation and the appointment for surgery would favor peripheral and central sensitization if pain is not controlled, making the pain chronic and making it independent of the injury.
Using aggressive perioperative analgesia (antihyperalgesics, regional blocks, and multimodal analgesia) during the peri-surgical period could reduce the incidence of CPSP (Figure 5).
Perioperative analgesia.
Chronic pain is common after hernia surgery. Patients with pain before the operation benefit from surgery, but some patients who have no pain before hernia repair surgery develop significant groin pain later. Watchful waiting has proven to be safe [28] and profitable [29] in patients with asymptomatic inguinal hernia. It is a theme of debate whether surgery is appropriate in asymptomatic hernias and possibly in some other interventions as well.
CPSP is a common entity in interventional procedures today. Progress continues in the standardization of prevention and treatment strategies for this delicate problem in the technical and organizational sphere.
The improvement efforts aim to:
Early identification of patients with preoperative pain who need intervention.
Avoid delaying this intervention as far as possible, and if there is a delay, provide adequate pain management until the time of surgery.
At the time of the intervention, determine the least invasive and most appropriate surgical technique for the pathology.
Implement the most appropriate perioperative anesthetic and analgesic techniques for the patient.
Once intervened, individualize postoperative analgesia so that APSP is as low as possible, thus avoiding, as far as possible, chronic pain.
Thanks to Merche and Eduardo, for giving me the opportunity to study without worrying about anything else. To Monica, for her patience in preparing this chapter and to Alaitz and Inhar, for their fun distractions.
I declare that I have no conflict of interests.
IntechOpen's Authorship Policy is based on ICMJE criteria for authorship. An Author, one must:
',metaTitle:"Authorship Policy",metaDescription:"IN TECH's Authorship Policy is based on ICMJE criteria for authorship. In order to be identified as an Author, one must:",metaKeywords:null,canonicalURL:"/page/authorship-policy",contentRaw:'[{"type":"htmlEditorComponent","content":"All contributors who meet these criteria are listed as Authors. Their exact contributions should be described in the manuscript at the time of submission.
\\n\\nConversely, all contributors who do not meet these criteria should be listed in the Acknowledgments section of the manuscript, along with a short description of their specific contributions.
\\n\\nCHANGES IN AUTHORSHIP
\\n\\nIf it is felt necessary to make changes to the list of Authors after a manuscript has been submitted or published, it is the responsibility of the Author concerned to provide a valid reason to amend the published list. Additionally, all listed Authors must verify and approve the proposed changes in order for any amendments to be made.
\\n\\nAFFILIATION
\\n\\nAuthors are responsible for ensuring all addresses and emails provided are correct. Under affiliation(s) all Authors should indicate where the research was conducted. Please note that no changes to the affiliation(s) can be made after the chapter has been published.
\\n\\nPolicy last updated: 2017-05-29
\\n"}]'},components:[{type:"htmlEditorComponent",content:"All contributors who meet these criteria are listed as Authors. Their exact contributions should be described in the manuscript at the time of submission.
\n\nConversely, all contributors who do not meet these criteria should be listed in the Acknowledgments section of the manuscript, along with a short description of their specific contributions.
\n\nCHANGES IN AUTHORSHIP
\n\nIf it is felt necessary to make changes to the list of Authors after a manuscript has been submitted or published, it is the responsibility of the Author concerned to provide a valid reason to amend the published list. Additionally, all listed Authors must verify and approve the proposed changes in order for any amendments to be made.
\n\nAFFILIATION
\n\nAuthors are responsible for ensuring all addresses and emails provided are correct. Under affiliation(s) all Authors should indicate where the research was conducted. Please note that no changes to the affiliation(s) can be made after the chapter has been published.
\n\nPolicy last updated: 2017-05-29
\n"}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"6700",title:"Dr.",name:"Abbass A.",middleName:null,surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6700/images/1864_n.jpg",biography:"Currently I am carrying out research in several areas of interest, mainly covering work on chemical and bio-sensors, semiconductor thin film device fabrication and characterisation.\nAt the moment I have very strong interest in radiation environmental pollution and bacteriology treatment. The teams of researchers are working very hard to bring novel results in this field. I am also a member of the team in charge for the supervision of Ph.D. students in the fields of development of silicon based planar waveguide sensor devices, study of inelastic electron tunnelling in planar tunnelling nanostructures for sensing applications and development of organotellurium(IV) compounds for semiconductor applications. I am a specialist in data analysis techniques and nanosurface structure. I have served as the editor for many books, been a member of the editorial board in science journals, have published many papers and hold many patents.",institutionString:null,institution:{name:"Sheffield Hallam University",country:{name:"United Kingdom"}}},{id:"54525",title:"Prof.",name:"Abdul Latif",middleName:null,surname:"Ahmad",slug:"abdul-latif-ahmad",fullName:"Abdul Latif Ahmad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"47940",title:"Dr.",name:"Alberto",middleName:null,surname:"Mantovani",slug:"alberto-mantovani",fullName:"Alberto Mantovani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"12392",title:"Mr.",name:"Alex",middleName:null,surname:"Lazinica",slug:"alex-lazinica",fullName:"Alex Lazinica",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12392/images/7282_n.png",biography:"Alex Lazinica is the founder and CEO of IntechOpen. After obtaining a Master's degree in Mechanical Engineering, he continued his PhD studies in Robotics at the Vienna University of Technology. Here he worked as a robotic researcher with the university's Intelligent Manufacturing Systems Group as well as a guest researcher at various European universities, including the Swiss Federal Institute of Technology Lausanne (EPFL). During this time he published more than 20 scientific papers, gave presentations, served as a reviewer for major robotic journals and conferences and most importantly he co-founded and built the International Journal of Advanced Robotic Systems- world's first Open Access journal in the field of robotics. Starting this journal was a pivotal point in his career, since it was a pathway to founding IntechOpen - Open Access publisher focused on addressing academic researchers needs. Alex is a personification of IntechOpen key values being trusted, open and entrepreneurial. Today his focus is on defining the growth and development strategy for the company.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"19816",title:"Prof.",name:"Alexander",middleName:null,surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/19816/images/1607_n.jpg",biography:"Alexander I. Kokorin: born: 1947, Moscow; DSc., PhD; Principal Research Fellow (Research Professor) of Department of Kinetics and Catalysis, N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow.\r\nArea of research interests: physical chemistry of complex-organized molecular and nanosized systems, including polymer-metal complexes; the surface of doped oxide semiconductors. He is an expert in structural, absorptive, catalytic and photocatalytic properties, in structural organization and dynamic features of ionic liquids, in magnetic interactions between paramagnetic centers. The author or co-author of 3 books, over 200 articles and reviews in scientific journals and books. He is an actual member of the International EPR/ESR Society, European Society on Quantum Solar Energy Conversion, Moscow House of Scientists, of the Board of Moscow Physical Society.",institutionString:null,institution:{name:"Semenov Institute of Chemical Physics",country:{name:"Russia"}}},{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62389/images/3413_n.jpg",biography:"Dr. Ali Demir Sezer has a Ph.D. from Pharmaceutical Biotechnology at the Faculty of Pharmacy, University of Marmara (Turkey). He is the member of many Pharmaceutical Associations and acts as a reviewer of scientific journals and European projects under different research areas such as: drug delivery systems, nanotechnology and pharmaceutical biotechnology. Dr. Sezer is the author of many scientific publications in peer-reviewed journals and poster communications. Focus of his research activity is drug delivery, physico-chemical characterization and biological evaluation of biopolymers micro and nanoparticles as modified drug delivery system, and colloidal drug carriers (liposomes, nanoparticles etc.).",institutionString:null,institution:{name:"Marmara University",country:{name:"Turkey"}}},{id:"61051",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"100762",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"St David's Medical Center",country:{name:"United States of America"}}},{id:"107416",title:"Dr.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Texas Cardiac Arrhythmia",country:{name:"United States of America"}}},{id:"64434",title:"Dr.",name:"Angkoon",middleName:null,surname:"Phinyomark",slug:"angkoon-phinyomark",fullName:"Angkoon Phinyomark",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/64434/images/2619_n.jpg",biography:"My name is Angkoon Phinyomark. I received a B.Eng. degree in Computer Engineering with First Class Honors in 2008 from Prince of Songkla University, Songkhla, Thailand, where I received a Ph.D. degree in Electrical Engineering. My research interests are primarily in the area of biomedical signal processing and classification notably EMG (electromyography signal), EOG (electrooculography signal), and EEG (electroencephalography signal), image analysis notably breast cancer analysis and optical coherence tomography, and rehabilitation engineering. I became a student member of IEEE in 2008. During October 2011-March 2012, I had worked at School of Computer Science and Electronic Engineering, University of Essex, Colchester, Essex, United Kingdom. In addition, during a B.Eng. I had been a visiting research student at Faculty of Computer Science, University of Murcia, Murcia, Spain for three months.\n\nI have published over 40 papers during 5 years in refereed journals, books, and conference proceedings in the areas of electro-physiological signals processing and classification, notably EMG and EOG signals, fractal analysis, wavelet analysis, texture analysis, feature extraction and machine learning algorithms, and assistive and rehabilitative devices. I have several computer programming language certificates, i.e. Sun Certified Programmer for the Java 2 Platform 1.4 (SCJP), Microsoft Certified Professional Developer, Web Developer (MCPD), Microsoft Certified Technology Specialist, .NET Framework 2.0 Web (MCTS). I am a Reviewer for several refereed journals and international conferences, such as IEEE Transactions on Biomedical Engineering, IEEE Transactions on Industrial Electronics, Optic Letters, Measurement Science Review, and also a member of the International Advisory Committee for 2012 IEEE Business Engineering and Industrial Applications and 2012 IEEE Symposium on Business, Engineering and Industrial Applications.",institutionString:null,institution:{name:"Joseph Fourier University",country:{name:"France"}}},{id:"55578",title:"Dr.",name:"Antonio",middleName:null,surname:"Jurado-Navas",slug:"antonio-jurado-navas",fullName:"Antonio Jurado-Navas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/55578/images/4574_n.png",biography:"Antonio Jurado-Navas received the M.S. degree (2002) and the Ph.D. degree (2009) in Telecommunication Engineering, both from the University of Málaga (Spain). He first worked as a consultant at Vodafone-Spain. From 2004 to 2011, he was a Research Assistant with the Communications Engineering Department at the University of Málaga. In 2011, he became an Assistant Professor in the same department. From 2012 to 2015, he was with Ericsson Spain, where he was working on geo-location\ntools for third generation mobile networks. Since 2015, he is a Marie-Curie fellow at the Denmark Technical University. His current research interests include the areas of mobile communication systems and channel modeling in addition to atmospheric optical communications, adaptive optics and statistics",institutionString:null,institution:{name:"University of Malaga",country:{name:"Spain"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5681},{group:"region",caption:"Middle and South America",value:2,count:5161},{group:"region",caption:"Africa",value:3,count:1683},{group:"region",caption:"Asia",value:4,count:10200},{group:"region",caption:"Australia and Oceania",value:5,count:886},{group:"region",caption:"Europe",value:6,count:15610}],offset:12,limit:12,total:117095},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{sort:"dateendthirdsteppublish"},books:[],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:9},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:17},{group:"topic",caption:"Business, Management and Economics",value:7,count:2},{group:"topic",caption:"Chemistry",value:8,count:7},{group:"topic",caption:"Computer and Information Science",value:9,count:10},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:5},{group:"topic",caption:"Engineering",value:11,count:15},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:5},{group:"topic",caption:"Materials Science",value:14,count:4},{group:"topic",caption:"Mathematics",value:15,count:1},{group:"topic",caption:"Medicine",value:16,count:60},{group:"topic",caption:"Nanotechnology and Nanomaterials",value:17,count:1},{group:"topic",caption:"Neuroscience",value:18,count:1},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:6},{group:"topic",caption:"Physics",value:20,count:2},{group:"topic",caption:"Psychology",value:21,count:3},{group:"topic",caption:"Robotics",value:22,count:1},{group:"topic",caption:"Social Sciences",value:23,count:3},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:2}],offset:0,limit:12,total:null},popularBooks:{featuredBooks:[{type:"book",id:"9343",title:"Trace Metals in the Environment",subtitle:"New Approaches and Recent Advances",isOpenForSubmission:!1,hash:"ae07e345bc2ce1ebbda9f70c5cd12141",slug:"trace-metals-in-the-environment-new-approaches-and-recent-advances",bookSignature:"Mario Alfonso Murillo-Tovar, Hugo Saldarriaga-Noreña and Agnieszka Saeid",coverURL:"https://cdn.intechopen.com/books/images_new/9343.jpg",editors:[{id:"255959",title:"Dr.",name:"Mario Alfonso",middleName:null,surname:"Murillo-Tovar",slug:"mario-alfonso-murillo-tovar",fullName:"Mario Alfonso Murillo-Tovar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7769",title:"Medical Isotopes",subtitle:null,isOpenForSubmission:!1,hash:"f8d3c5a6c9a42398e56b4e82264753f7",slug:"medical-isotopes",bookSignature:"Syed Ali Raza Naqvi and Muhammad Babar Imrani",coverURL:"https://cdn.intechopen.com/books/images_new/7769.jpg",editors:[{id:"259190",title:"Dr.",name:"Syed Ali Raza",middleName:null,surname:"Naqvi",slug:"syed-ali-raza-naqvi",fullName:"Syed Ali Raza Naqvi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9376",title:"Contemporary Developments and Perspectives in International Health Security",subtitle:"Volume 1",isOpenForSubmission:!1,hash:"b9a00b84cd04aae458fb1d6c65795601",slug:"contemporary-developments-and-perspectives-in-international-health-security-volume-1",bookSignature:"Stanislaw P. Stawicki, Michael S. Firstenberg, Sagar C. Galwankar, Ricardo Izurieta and Thomas Papadimos",coverURL:"https://cdn.intechopen.com/books/images_new/9376.jpg",editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7831",title:"Sustainability in Urban Planning and Design",subtitle:null,isOpenForSubmission:!1,hash:"c924420492c8c2c9751e178d025f4066",slug:"sustainability-in-urban-planning-and-design",bookSignature:"Amjad Almusaed, Asaad Almssad and Linh Truong - Hong",coverURL:"https://cdn.intechopen.com/books/images_new/7831.jpg",editors:[{id:"110471",title:"Dr.",name:"Amjad",middleName:"Zaki",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9279",title:"Concepts, Applications and Emerging Opportunities in Industrial Engineering",subtitle:null,isOpenForSubmission:!1,hash:"9bfa87f9b627a5468b7c1e30b0eea07a",slug:"concepts-applications-and-emerging-opportunities-in-industrial-engineering",bookSignature:"Gary Moynihan",coverURL:"https://cdn.intechopen.com/books/images_new/9279.jpg",editors:[{id:"16974",title:"Dr.",name:"Gary",middleName:null,surname:"Moynihan",slug:"gary-moynihan",fullName:"Gary Moynihan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7807",title:"A Closer Look at Organizational Culture in Action",subtitle:null,isOpenForSubmission:!1,hash:"05c608b9271cc2bc711f4b28748b247b",slug:"a-closer-look-at-organizational-culture-in-action",bookSignature:"Süleyman Davut Göker",coverURL:"https://cdn.intechopen.com/books/images_new/7807.jpg",editors:[{id:"190035",title:"Associate Prof.",name:"Süleyman Davut",middleName:null,surname:"Göker",slug:"suleyman-davut-goker",fullName:"Süleyman Davut Göker"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7796",title:"Human 4.0",subtitle:"From Biology to Cybernetic",isOpenForSubmission:!1,hash:"5ac5c052d3a593d5c4f4df66d005e5af",slug:"human-4-0-from-biology-to-cybernetic",bookSignature:"Yves Rybarczyk",coverURL:"https://cdn.intechopen.com/books/images_new/7796.jpg",editors:[{id:"72920",title:"Prof.",name:"Yves",middleName:"Philippe",surname:"Rybarczyk",slug:"yves-rybarczyk",fullName:"Yves Rybarczyk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9711",title:"Pests, Weeds and Diseases in Agricultural Crop and Animal Husbandry Production",subtitle:null,isOpenForSubmission:!1,hash:"12cf675f1e433135dd5bf5df7cec124f",slug:"pests-weeds-and-diseases-in-agricultural-crop-and-animal-husbandry-production",bookSignature:"Dimitrios Kontogiannatos, Anna Kourti and Kassio Ferreira Mendes",coverURL:"https://cdn.intechopen.com/books/images_new/9711.jpg",editors:[{id:"196691",title:"Dr.",name:"Dimitrios",middleName:null,surname:"Kontogiannatos",slug:"dimitrios-kontogiannatos",fullName:"Dimitrios Kontogiannatos"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10178",title:"Environmental Emissions",subtitle:null,isOpenForSubmission:!1,hash:"febf21ec717bfe20ae25a9dab9b5d438",slug:"environmental-emissions",bookSignature:"Richard Viskup",coverURL:"https://cdn.intechopen.com/books/images_new/10178.jpg",editors:[{id:"103742",title:"Dr.",name:"Richard",middleName:null,surname:"Viskup",slug:"richard-viskup",fullName:"Richard Viskup"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8511",title:"Cyberspace",subtitle:null,isOpenForSubmission:!1,hash:"8c1cdeb133dbe6cc1151367061c1bba6",slug:"cyberspace",bookSignature:"Evon Abu-Taieh, Abdelkrim El Mouatasim and Issam H. Al Hadid",coverURL:"https://cdn.intechopen.com/books/images_new/8511.jpg",editors:[{id:"223522",title:"Dr.",name:"Evon",middleName:"M.O.",surname:"Abu-Taieh",slug:"evon-abu-taieh",fullName:"Evon Abu-Taieh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9534",title:"Banking and Finance",subtitle:null,isOpenForSubmission:!1,hash:"af14229738af402c3b595d7e124dce82",slug:"banking-and-finance",bookSignature:"Razali Haron, Maizaitulaidawati Md Husin and Michael Murg",coverURL:"https://cdn.intechopen.com/books/images_new/9534.jpg",editors:[{id:"206517",title:"Prof.",name:"Razali",middleName:null,surname:"Haron",slug:"razali-haron",fullName:"Razali Haron"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"2160",title:"MATLAB",subtitle:"A Fundamental Tool for Scientific Computing and Engineering Applications - Volume 1",isOpenForSubmission:!1,hash:"dd9c658341fbd264ed4f8d9e6aa8ca29",slug:"matlab-a-fundamental-tool-for-scientific-computing-and-engineering-applications-volume-1",bookSignature:"Vasilios N. Katsikis",coverURL:"https://cdn.intechopen.com/books/images_new/2160.jpg",editors:[{id:"12289",title:"Prof.",name:"Vasilios",middleName:"N.",surname:"Katsikis",slug:"vasilios-katsikis",fullName:"Vasilios Katsikis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5126},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"9343",title:"Trace Metals in the Environment",subtitle:"New Approaches and Recent Advances",isOpenForSubmission:!1,hash:"ae07e345bc2ce1ebbda9f70c5cd12141",slug:"trace-metals-in-the-environment-new-approaches-and-recent-advances",bookSignature:"Mario Alfonso Murillo-Tovar, Hugo Saldarriaga-Noreña and Agnieszka Saeid",coverURL:"https://cdn.intechopen.com/books/images_new/9343.jpg",editors:[{id:"255959",title:"Dr.",name:"Mario Alfonso",middleName:null,surname:"Murillo-Tovar",slug:"mario-alfonso-murillo-tovar",fullName:"Mario Alfonso Murillo-Tovar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7769",title:"Medical Isotopes",subtitle:null,isOpenForSubmission:!1,hash:"f8d3c5a6c9a42398e56b4e82264753f7",slug:"medical-isotopes",bookSignature:"Syed Ali Raza Naqvi and Muhammad Babar Imrani",coverURL:"https://cdn.intechopen.com/books/images_new/7769.jpg",editors:[{id:"259190",title:"Dr.",name:"Syed Ali Raza",middleName:null,surname:"Naqvi",slug:"syed-ali-raza-naqvi",fullName:"Syed Ali Raza Naqvi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9376",title:"Contemporary Developments and Perspectives in International Health Security",subtitle:"Volume 1",isOpenForSubmission:!1,hash:"b9a00b84cd04aae458fb1d6c65795601",slug:"contemporary-developments-and-perspectives-in-international-health-security-volume-1",bookSignature:"Stanislaw P. Stawicki, Michael S. Firstenberg, Sagar C. Galwankar, Ricardo Izurieta and Thomas Papadimos",coverURL:"https://cdn.intechopen.com/books/images_new/9376.jpg",editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7831",title:"Sustainability in Urban Planning and Design",subtitle:null,isOpenForSubmission:!1,hash:"c924420492c8c2c9751e178d025f4066",slug:"sustainability-in-urban-planning-and-design",bookSignature:"Amjad Almusaed, Asaad Almssad and Linh Truong - Hong",coverURL:"https://cdn.intechopen.com/books/images_new/7831.jpg",editors:[{id:"110471",title:"Dr.",name:"Amjad",middleName:"Zaki",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9279",title:"Concepts, Applications and Emerging Opportunities in Industrial Engineering",subtitle:null,isOpenForSubmission:!1,hash:"9bfa87f9b627a5468b7c1e30b0eea07a",slug:"concepts-applications-and-emerging-opportunities-in-industrial-engineering",bookSignature:"Gary Moynihan",coverURL:"https://cdn.intechopen.com/books/images_new/9279.jpg",editors:[{id:"16974",title:"Dr.",name:"Gary",middleName:null,surname:"Moynihan",slug:"gary-moynihan",fullName:"Gary Moynihan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7807",title:"A Closer Look at Organizational Culture in Action",subtitle:null,isOpenForSubmission:!1,hash:"05c608b9271cc2bc711f4b28748b247b",slug:"a-closer-look-at-organizational-culture-in-action",bookSignature:"Süleyman Davut Göker",coverURL:"https://cdn.intechopen.com/books/images_new/7807.jpg",editors:[{id:"190035",title:"Associate Prof.",name:"Süleyman Davut",middleName:null,surname:"Göker",slug:"suleyman-davut-goker",fullName:"Süleyman Davut Göker"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7796",title:"Human 4.0",subtitle:"From Biology to Cybernetic",isOpenForSubmission:!1,hash:"5ac5c052d3a593d5c4f4df66d005e5af",slug:"human-4-0-from-biology-to-cybernetic",bookSignature:"Yves Rybarczyk",coverURL:"https://cdn.intechopen.com/books/images_new/7796.jpg",editors:[{id:"72920",title:"Prof.",name:"Yves",middleName:"Philippe",surname:"Rybarczyk",slug:"yves-rybarczyk",fullName:"Yves Rybarczyk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9711",title:"Pests, Weeds and Diseases in Agricultural Crop and Animal Husbandry Production",subtitle:null,isOpenForSubmission:!1,hash:"12cf675f1e433135dd5bf5df7cec124f",slug:"pests-weeds-and-diseases-in-agricultural-crop-and-animal-husbandry-production",bookSignature:"Dimitrios Kontogiannatos, Anna Kourti and Kassio Ferreira Mendes",coverURL:"https://cdn.intechopen.com/books/images_new/9711.jpg",editors:[{id:"196691",title:"Dr.",name:"Dimitrios",middleName:null,surname:"Kontogiannatos",slug:"dimitrios-kontogiannatos",fullName:"Dimitrios Kontogiannatos"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10178",title:"Environmental Emissions",subtitle:null,isOpenForSubmission:!1,hash:"febf21ec717bfe20ae25a9dab9b5d438",slug:"environmental-emissions",bookSignature:"Richard Viskup",coverURL:"https://cdn.intechopen.com/books/images_new/10178.jpg",editors:[{id:"103742",title:"Dr.",name:"Richard",middleName:null,surname:"Viskup",slug:"richard-viskup",fullName:"Richard Viskup"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8511",title:"Cyberspace",subtitle:null,isOpenForSubmission:!1,hash:"8c1cdeb133dbe6cc1151367061c1bba6",slug:"cyberspace",bookSignature:"Evon Abu-Taieh, Abdelkrim El Mouatasim and Issam H. Al Hadid",coverURL:"https://cdn.intechopen.com/books/images_new/8511.jpg",editors:[{id:"223522",title:"Dr.",name:"Evon",middleName:"M.O.",surname:"Abu-Taieh",slug:"evon-abu-taieh",fullName:"Evon Abu-Taieh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"8468",title:"Sheep Farming",subtitle:"An Approach to Feed, Growth and Sanity",isOpenForSubmission:!1,hash:"838f08594850bc04aa14ec873ed1b96f",slug:"sheep-farming-an-approach-to-feed-growth-and-sanity",bookSignature:"António Monteiro",coverURL:"https://cdn.intechopen.com/books/images_new/8468.jpg",editedByType:"Edited by",editors:[{id:"190314",title:"Prof.",name:"António",middleName:"Cardoso",surname:"Monteiro",slug:"antonio-monteiro",fullName:"António Monteiro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9523",title:"Oral and Maxillofacial Surgery",subtitle:null,isOpenForSubmission:!1,hash:"5eb6ec2db961a6c8965d11180a58d5c1",slug:"oral-and-maxillofacial-surgery",bookSignature:"Gokul Sridharan",coverURL:"https://cdn.intechopen.com/books/images_new/9523.jpg",editedByType:"Edited by",editors:[{id:"82453",title:"Dr.",name:"Gokul",middleName:null,surname:"Sridharan",slug:"gokul-sridharan",fullName:"Gokul Sridharan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9785",title:"Endometriosis",subtitle:null,isOpenForSubmission:!1,hash:"f457ca61f29cf7e8bc191732c50bb0ce",slug:"endometriosis",bookSignature:"Courtney Marsh",coverURL:"https://cdn.intechopen.com/books/images_new/9785.jpg",editedByType:"Edited by",editors:[{id:"255491",title:"Dr.",name:"Courtney",middleName:null,surname:"Marsh",slug:"courtney-marsh",fullName:"Courtney Marsh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9018",title:"Some RNA Viruses",subtitle:null,isOpenForSubmission:!1,hash:"a5cae846dbe3692495fc4add2f60fd84",slug:"some-rna-viruses",bookSignature:"Yogendra Shah and Eltayb Abuelzein",coverURL:"https://cdn.intechopen.com/books/images_new/9018.jpg",editedByType:"Edited by",editors:[{id:"278914",title:"Ph.D.",name:"Yogendra",middleName:null,surname:"Shah",slug:"yogendra-shah",fullName:"Yogendra Shah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8816",title:"Financial Crises",subtitle:"A Selection of Readings",isOpenForSubmission:!1,hash:"6f2f49fb903656e4e54280c79fabd10c",slug:"financial-crises-a-selection-of-readings",bookSignature:"Stelios Markoulis",coverURL:"https://cdn.intechopen.com/books/images_new/8816.jpg",editedByType:"Edited by",editors:[{id:"237863",title:"Dr.",name:"Stelios",middleName:null,surname:"Markoulis",slug:"stelios-markoulis",fullName:"Stelios Markoulis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9585",title:"Advances in Complex Valvular Disease",subtitle:null,isOpenForSubmission:!1,hash:"ef64f11e211621ecfe69c46e60e7ca3d",slug:"advances-in-complex-valvular-disease",bookSignature:"Michael S. Firstenberg and Imran Khan",coverURL:"https://cdn.intechopen.com/books/images_new/9585.jpg",editedByType:"Edited by",editors:[{id:"64343",title:null,name:"Michael S.",middleName:"S",surname:"Firstenberg",slug:"michael-s.-firstenberg",fullName:"Michael S. Firstenberg"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10150",title:"Smart Manufacturing",subtitle:"When Artificial Intelligence Meets the Internet of Things",isOpenForSubmission:!1,hash:"87004a19de13702d042f8ff96d454698",slug:"smart-manufacturing-when-artificial-intelligence-meets-the-internet-of-things",bookSignature:"Tan Yen Kheng",coverURL:"https://cdn.intechopen.com/books/images_new/10150.jpg",editedByType:"Edited by",editors:[{id:"78857",title:"Dr.",name:"Tan Yen",middleName:null,surname:"Kheng",slug:"tan-yen-kheng",fullName:"Tan Yen Kheng"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9386",title:"Direct Numerical Simulations",subtitle:"An Introduction and Applications",isOpenForSubmission:!1,hash:"158a3a0fdba295d21ff23326f5a072d5",slug:"direct-numerical-simulations-an-introduction-and-applications",bookSignature:"Srinivasa Rao",coverURL:"https://cdn.intechopen.com/books/images_new/9386.jpg",editedByType:"Edited by",editors:[{id:"6897",title:"Dr.",name:"Srinivasa",middleName:"P",surname:"Rao",slug:"srinivasa-rao",fullName:"Srinivasa Rao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editedByType:"Edited by",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9208",title:"Welding",subtitle:"Modern Topics",isOpenForSubmission:!1,hash:"7d6be076ccf3a3f8bd2ca52d86d4506b",slug:"welding-modern-topics",bookSignature:"Sadek Crisóstomo Absi Alfaro, Wojciech Borek and Błażej Tomiczek",coverURL:"https://cdn.intechopen.com/books/images_new/9208.jpg",editedByType:"Edited by",editors:[{id:"65292",title:"Prof.",name:"Sadek Crisostomo Absi",middleName:"C. Absi",surname:"Alfaro",slug:"sadek-crisostomo-absi-alfaro",fullName:"Sadek Crisostomo Absi Alfaro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"282",title:"Biomedical Engineering",slug:"technology-biomedical-engineering",parent:{title:"Technology",slug:"technology"},numberOfBooks:7,numberOfAuthorsAndEditors:159,numberOfWosCitations:33,numberOfCrossrefCitations:53,numberOfDimensionsCitations:135,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"technology-biomedical-engineering",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"9048",title:"Current and Future Aspects of Nanomedicine",subtitle:null,isOpenForSubmission:!1,hash:"c34656bf6a7c08401e1108338c2a1bf6",slug:"current-and-future-aspects-of-nanomedicine",bookSignature:"Islam Ahmed Hamed Khalil",coverURL:"https://cdn.intechopen.com/books/images_new/9048.jpg",editedByType:"Edited by",editors:[{id:"226598",title:"Dr.",name:"Islam",middleName:null,surname:"Khalil",slug:"islam-khalil",fullName:"Islam Khalil"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7594",title:"Current Topics in Biochemical Engineering",subtitle:null,isOpenForSubmission:!1,hash:"391609f1f0cb3bba32befeb3aa40ccf3",slug:"current-topics-in-biochemical-engineering",bookSignature:"Naofumi Shiomi",coverURL:"https://cdn.intechopen.com/books/images_new/7594.jpg",editedByType:"Edited by",editors:[{id:"163777",title:"Prof.",name:"Naofumi",middleName:null,surname:"Shiomi",slug:"naofumi-shiomi",fullName:"Naofumi Shiomi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8646",title:"Systems Biology",subtitle:null,isOpenForSubmission:!1,hash:"e7735d2fe6193b7b256c7098be4adcf4",slug:"systems-biology",bookSignature:"Dimitrios Vlachakis",coverURL:"https://cdn.intechopen.com/books/images_new/8646.jpg",editedByType:"Edited by",editors:[{id:"179110",title:"Dr.",name:"Dimitrios",middleName:"P.",surname:"Vlachakis",slug:"dimitrios-vlachakis",fullName:"Dimitrios Vlachakis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7437",title:"Nanomedicines",subtitle:null,isOpenForSubmission:!1,hash:"0e1f5f6258f074c533976c4f4d248568",slug:"nanomedicines",bookSignature:"Muhammad Akhyar Farrukh",coverURL:"https://cdn.intechopen.com/books/images_new/7437.jpg",editedByType:"Edited by",editors:[{id:"63182",title:"Dr.",name:"Muhammad Akhyar",middleName:null,surname:"Farrukh",slug:"muhammad-akhyar-farrukh",fullName:"Muhammad Akhyar Farrukh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5951",title:"Biomaterials in Regenerative Medicine",subtitle:null,isOpenForSubmission:!1,hash:"a4ff8af6190bb48a5857450c9c2612d7",slug:"biomaterials-in-regenerative-medicine",bookSignature:"Leszek A. Dobrzański",coverURL:"https://cdn.intechopen.com/books/images_new/5951.jpg",editedByType:"Edited by",editors:[{id:"15880",title:"Prof.",name:"Leszek A.",middleName:null,surname:"Dobrzański",slug:"leszek-a.-dobrzanski",fullName:"Leszek A. Dobrzański"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5874",title:"Structural Health Monitoring",subtitle:"Measurement Methods and Practical Applications",isOpenForSubmission:!1,hash:"72f61895d84252f6f5b92b7625741743",slug:"structural-health-monitoring-measurement-methods-and-practical-applications",bookSignature:"Moises Rivas-Lopez, Wendy Flores Fuentes and Oleg Sergiyenko",coverURL:"https://cdn.intechopen.com/books/images_new/5874.jpg",editedByType:"Edited by",editors:[{id:"178178",title:"Dr.",name:"Moises",middleName:null,surname:"Rivas-Lopez",slug:"moises-rivas-lopez",fullName:"Moises Rivas-Lopez"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1649",title:"Electrostatics",subtitle:null,isOpenForSubmission:!1,hash:"c0630d15c7e3fc8f85f239750051ef7f",slug:"electrostatics",bookSignature:"Huseyin Canbolat",coverURL:"https://cdn.intechopen.com/books/images_new/1649.jpg",editedByType:"Edited by",editors:[{id:"5887",title:"Dr.",name:"Hüseyin",middleName:null,surname:"Canbolat",slug:"huseyin-canbolat",fullName:"Hüseyin Canbolat"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:7,mostCitedChapters:[{id:"62943",doi:"10.5772/intechopen.80238",title:"Silver Nanoparticles as Multi-Functional Drug Delivery Systems",slug:"silver-nanoparticles-as-multi-functional-drug-delivery-systems",totalDownloads:2492,totalCrossrefCites:6,totalDimensionsCites:19,book:{slug:"nanomedicines",title:"Nanomedicines",fullTitle:"Nanomedicines"},signatures:"Nadezhda Ivanova, Viliana Gugleva, Mirena Dobreva, Ivaylo\nPehlivanov, Stefan Stefanov and Velichka Andonova",authors:[{id:"202958",title:"Dr.",name:"Velichka",middleName:null,surname:"Andonova",slug:"velichka-andonova",fullName:"Velichka Andonova"},{id:"265332",title:"MSc.",name:"Nadezhda",middleName:null,surname:"Ivanova",slug:"nadezhda-ivanova",fullName:"Nadezhda Ivanova"},{id:"265333",title:"MSc.",name:"Viliana",middleName:null,surname:"Gugleva",slug:"viliana-gugleva",fullName:"Viliana Gugleva"},{id:"265334",title:"MSc.",name:"Mirena",middleName:null,surname:"Dobreva",slug:"mirena-dobreva",fullName:"Mirena Dobreva"},{id:"265335",title:"Mr.",name:"Stefan",middleName:"Radnev",surname:"Stefanov",slug:"stefan-stefanov",fullName:"Stefan Stefanov"},{id:"265336",title:"MSc.",name:"Ivaylo",middleName:null,surname:"Pehlivanov",slug:"ivaylo-pehlivanov",fullName:"Ivaylo Pehlivanov"}]},{id:"56634",doi:"10.5772/intechopen.70122",title:"Biomaterials and Stem Cells: Promising Tools in Tissue Engineering and Biomedical Applications",slug:"biomaterials-and-stem-cells-promising-tools-in-tissue-engineering-and-biomedical-applications",totalDownloads:998,totalCrossrefCites:5,totalDimensionsCites:14,book:{slug:"biomaterials-in-regenerative-medicine",title:"Biomaterials in Regenerative Medicine",fullTitle:"Biomaterials in Regenerative Medicine"},signatures:"Małgorzata Sekuła and Ewa K. Zuba‐Surma",authors:[{id:"202773",title:"Prof.",name:"Ewa",middleName:null,surname:"Zuba-Surma",slug:"ewa-zuba-surma",fullName:"Ewa Zuba-Surma"},{id:"202775",title:"Dr.",name:"Malgorzata",middleName:null,surname:"Sekula",slug:"malgorzata-sekula",fullName:"Malgorzata Sekula"}]},{id:"56100",doi:"10.5772/intechopen.69718",title:"Properties of Co-Cr Dental Alloys Fabricated Using Additive Technologies",slug:"properties-of-co-cr-dental-alloys-fabricated-using-additive-technologies",totalDownloads:954,totalCrossrefCites:4,totalDimensionsCites:12,book:{slug:"biomaterials-in-regenerative-medicine",title:"Biomaterials in Regenerative Medicine",fullTitle:"Biomaterials in Regenerative Medicine"},signatures:"Tsanka Dikova",authors:[{id:"205539",title:"Dr.",name:"Tsanka",middleName:null,surname:"Dikova",slug:"tsanka-dikova",fullName:"Tsanka Dikova"}]}],mostDownloadedChaptersLast30Days:[{id:"65234",title:"Integrated Biologics Manufacturing in Stirred-Suspension Bioreactor: A Stem Cell Perspective",slug:"integrated-biologics-manufacturing-in-stirred-suspension-bioreactor-a-stem-cell-perspective",totalDownloads:664,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"current-topics-in-biochemical-engineering",title:"Current Topics in Biochemical Engineering",fullTitle:"Current Topics in Biochemical Engineering"},signatures:"Suman C. Nath and Derrick E. Rancourt",authors:[{id:"62721",title:"Dr.",name:"Derrick E.",middleName:null,surname:"Rancourt",slug:"derrick-e.-rancourt",fullName:"Derrick E. Rancourt"},{id:"272287",title:"Dr.",name:"Suman",middleName:null,surname:"Nath",slug:"suman-nath",fullName:"Suman Nath"}]},{id:"56701",title:"Hydrogels in Regenerative Medicine",slug:"hydrogels-in-regenerative-medicine",totalDownloads:971,totalCrossrefCites:1,totalDimensionsCites:5,book:{slug:"biomaterials-in-regenerative-medicine",title:"Biomaterials in Regenerative Medicine",fullTitle:"Biomaterials in Regenerative Medicine"},signatures:"Yasemin Budama-Kilinc, Rabia Cakir-Koc, Bahar Aslan, Burcu Özkan,\nHande Mutlu and Eslin Üstün",authors:[{id:"146042",title:"MSc.",name:"Rabia",middleName:null,surname:"Cakir Koc",slug:"rabia-cakir-koc",fullName:"Rabia Cakir Koc"},{id:"182570",title:"Dr.",name:"Yasemin",middleName:null,surname:"Budama Kilinc",slug:"yasemin-budama-kilinc",fullName:"Yasemin Budama Kilinc"}]},{id:"56131",title:"Tissue Engineering: Use of Growth Factors in Bone Regeneration",slug:"tissue-engineering-use-of-growth-factors-in-bone-regeneration",totalDownloads:986,totalCrossrefCites:0,totalDimensionsCites:1,book:{slug:"biomaterials-in-regenerative-medicine",title:"Biomaterials in Regenerative Medicine",fullTitle:"Biomaterials in Regenerative Medicine"},signatures:"Carmen Mortellaro and Massimo Del Fabbro",authors:[{id:"202745",title:"Prof.",name:"Carmen",middleName:null,surname:"Mortellaro",slug:"carmen-mortellaro",fullName:"Carmen Mortellaro"},{id:"204182",title:"Dr.",name:"Massimo",middleName:null,surname:"Del Fabbro",slug:"massimo-del-fabbro",fullName:"Massimo Del Fabbro"}]},{id:"56486",title:"Perspective of Additive Manufacturing Selective Laser Melting in Co-Cr-Mo Alloy in the Consolidation of Dental Prosthesis",slug:"perspective-of-additive-manufacturing-selective-laser-melting-in-co-cr-mo-alloy-in-the-consolidation",totalDownloads:975,totalCrossrefCites:1,totalDimensionsCites:3,book:{slug:"biomaterials-in-regenerative-medicine",title:"Biomaterials in Regenerative Medicine",fullTitle:"Biomaterials in Regenerative Medicine"},signatures:"Marcello Vertamatti Mergulhão, Carlos Eduardo Podestá and\nMaurício David Martins das Neves",authors:[{id:"205851",title:"M.Sc.",name:"Marcello",middleName:"V.",surname:"Mergulhão",slug:"marcello-mergulhao",fullName:"Marcello Mergulhão"},{id:"209107",title:"Prof.",name:"Dr. Maurício",middleName:null,surname:"David Martins Das Neves",slug:"dr.-mauricio-david-martins-das-neves",fullName:"Dr. Maurício David Martins Das Neves"},{id:"209119",title:"Mr.",name:"Carlos",middleName:null,surname:"Eduardo Podestá",slug:"carlos-eduardo-podesta",fullName:"Carlos Eduardo Podestá"}]},{id:"56100",title:"Properties of Co-Cr Dental Alloys Fabricated Using Additive Technologies",slug:"properties-of-co-cr-dental-alloys-fabricated-using-additive-technologies",totalDownloads:954,totalCrossrefCites:4,totalDimensionsCites:12,book:{slug:"biomaterials-in-regenerative-medicine",title:"Biomaterials in Regenerative Medicine",fullTitle:"Biomaterials in Regenerative Medicine"},signatures:"Tsanka Dikova",authors:[{id:"205539",title:"Dr.",name:"Tsanka",middleName:null,surname:"Dikova",slug:"tsanka-dikova",fullName:"Tsanka Dikova"}]},{id:"64476",title:"Fermentation: Metabolism, Kinetic Models, and Bioprocessing",slug:"fermentation-metabolism-kinetic-models-and-bioprocessing",totalDownloads:1578,totalCrossrefCites:1,totalDimensionsCites:3,book:{slug:"current-topics-in-biochemical-engineering",title:"Current Topics in Biochemical Engineering",fullTitle:"Current Topics in Biochemical Engineering"},signatures:"Carlos González-Figueredo, René Alejandro Flores-Estrella and Oscar A. Rojas-Rejón",authors:[{id:"262807",title:"Dr.",name:"Oscar A.",middleName:null,surname:"Rojas-Rejon",slug:"oscar-a.-rojas-rejon",fullName:"Oscar A. Rojas-Rejon"},{id:"262810",title:"Dr.",name:"Carlos",middleName:null,surname:"González-Figueredo",slug:"carlos-gonzalez-figueredo",fullName:"Carlos González-Figueredo"},{id:"263482",title:"Dr.",name:"Rene Alejandro",middleName:null,surname:"Flores Estrella",slug:"rene-alejandro-flores-estrella",fullName:"Rene Alejandro Flores Estrella"}]},{id:"63035",title:"Biological Function of Exosomes as Diagnostic Markers and Therapeutic Delivery Vehicles in Carcinogenesis and Infectious Diseases",slug:"biological-function-of-exosomes-as-diagnostic-markers-and-therapeutic-delivery-vehicles-in-carcinoge",totalDownloads:1349,totalCrossrefCites:7,totalDimensionsCites:12,book:{slug:"nanomedicines",title:"Nanomedicines",fullTitle:"Nanomedicines"},signatures:"Brennetta J. Crenshaw, Brian Sims and Qiana L. Matthews",authors:[{id:"254038",title:"Ph.D.",name:"Qiana",middleName:null,surname:"Matthews",slug:"qiana-matthews",fullName:"Qiana Matthews"},{id:"254039",title:"Ms.",name:"Brennetta",middleName:null,surname:"Crenshaw",slug:"brennetta-crenshaw",fullName:"Brennetta Crenshaw"},{id:"266042",title:"Dr.",name:"Brian",middleName:null,surname:"Sims",slug:"brian-sims",fullName:"Brian Sims"}]},{id:"58850",title:"Introductory Chapter: Multi-Aspect Bibliographic Analysis of the Synergy of Technical, Biological and Medical Sciences Concerning Materials and Technologies Used for Medical and Dental Implantable Devices",slug:"introductory-chapter-multi-aspect-bibliographic-analysis-of-the-synergy-of-technical-biological-and-",totalDownloads:887,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"biomaterials-in-regenerative-medicine",title:"Biomaterials in Regenerative Medicine",fullTitle:"Biomaterials in Regenerative Medicine"},signatures:"Leszek A. Dobrzański",authors:[{id:"15880",title:"Prof.",name:"Leszek A.",middleName:null,surname:"Dobrzański",slug:"leszek-a.-dobrzanski",fullName:"Leszek A. Dobrzański"}]},{id:"62943",title:"Silver Nanoparticles as Multi-Functional Drug Delivery Systems",slug:"silver-nanoparticles-as-multi-functional-drug-delivery-systems",totalDownloads:2492,totalCrossrefCites:6,totalDimensionsCites:19,book:{slug:"nanomedicines",title:"Nanomedicines",fullTitle:"Nanomedicines"},signatures:"Nadezhda Ivanova, Viliana Gugleva, Mirena Dobreva, Ivaylo\nPehlivanov, Stefan Stefanov and Velichka Andonova",authors:[{id:"202958",title:"Dr.",name:"Velichka",middleName:null,surname:"Andonova",slug:"velichka-andonova",fullName:"Velichka Andonova"},{id:"265332",title:"MSc.",name:"Nadezhda",middleName:null,surname:"Ivanova",slug:"nadezhda-ivanova",fullName:"Nadezhda Ivanova"},{id:"265333",title:"MSc.",name:"Viliana",middleName:null,surname:"Gugleva",slug:"viliana-gugleva",fullName:"Viliana Gugleva"},{id:"265334",title:"MSc.",name:"Mirena",middleName:null,surname:"Dobreva",slug:"mirena-dobreva",fullName:"Mirena Dobreva"},{id:"265335",title:"Mr.",name:"Stefan",middleName:"Radnev",surname:"Stefanov",slug:"stefan-stefanov",fullName:"Stefan Stefanov"},{id:"265336",title:"MSc.",name:"Ivaylo",middleName:null,surname:"Pehlivanov",slug:"ivaylo-pehlivanov",fullName:"Ivaylo Pehlivanov"}]},{id:"71549",title:"Introductory Chapter: Overview on Nanomedicine Market",slug:"introductory-chapter-overview-on-nanomedicine-market",totalDownloads:229,totalCrossrefCites:0,totalDimensionsCites:1,book:{slug:"current-and-future-aspects-of-nanomedicine",title:"Current and Future Aspects of Nanomedicine",fullTitle:"Current and Future Aspects of Nanomedicine"},signatures:"Islam Ahmed Hamed Khalil, Islam A. Arida and Mohamed Ahmed",authors:[{id:"226598",title:"Dr.",name:"Islam",middleName:null,surname:"Khalil",slug:"islam-khalil",fullName:"Islam Khalil"}]}],onlineFirstChaptersFilter:{topicSlug:"technology-biomedical-engineering",limit:3,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"onlineFirst.detail",path:"/online-first/abdominal-hernia-pain-chronification-mechanisms-after-hernia-surgery",hash:"",query:{},params:{chapter:"abdominal-hernia-pain-chronification-mechanisms-after-hernia-surgery"},fullPath:"/online-first/abdominal-hernia-pain-chronification-mechanisms-after-hernia-surgery",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()